BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85. [PMID: 20427778 DOI: 10.1056/NEJMoa0907929] [Cited by in Crossref: 1821] [Cited by in F6Publishing: 871] [Article Influence: 165.5] [Reference Citation Analysis]
Number Citing Articles
1 Selicean S, Wang C, Guixé-Muntet S, Stefanescu H, Kawada N, Gracia-Sancho J. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol Int 2021;15:36-50. [PMID: 33544313 DOI: 10.1007/s12072-021-10135-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lin P, Lu J, Wang Y, Gu W, Yu J, Zhao R. Naturally Occurring Stilbenoid TSG Reverses Non-Alcoholic Fatty Liver Diseases via Gut-Liver Axis. PLoS One 2015;10:e0140346. [PMID: 26474417 DOI: 10.1371/journal.pone.0140346] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
3 Takaki A, Kawano S, Uchida D, Takahara M, Hiraoka S, Okada H. Paradoxical Roles of Oxidative Stress Response in the Digestive System before and after Carcinogenesis. Cancers (Basel) 2019;11:E213. [PMID: 30781816 DOI: 10.3390/cancers11020213] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
4 Dharmalingam M, Yamasandhi PG. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Indian J Endocrinol Metab. 2018;22:421-428. [PMID: 30090738 DOI: 10.4103/ijem.ijem_585_17] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
5 Saran AR, Dave S, Zarrinpar A. Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease. Gastroenterology 2020;158:1948-1966.e1. [PMID: 32061597 DOI: 10.1053/j.gastro.2020.01.050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
6 Arrigo T, Leonardi S, Cuppari C, Manti S, Lanzafame A, D’Angelo G, Gitto E, Marseglia L, Salpietro C. Role of the diet as a link between oxidative stress and liver diseases. World J Gastroenterol 2015; 21(2): 384-395 [PMID: 25593454 DOI: 10.3748/wjg.v21.i2.384] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
7 Montesano A, Senesi P, Vacante F, Mollica G, Benedini S, Mariotti M, Luzi L, Terruzzi I. L-Carnitine counteracts in vitro fructose-induced hepatic steatosis through targeting oxidative stress markers. J Endocrinol Invest 2020;43:493-503. [PMID: 31705397 DOI: 10.1007/s40618-019-01134-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
8 Boland BS, Edelman SV, Wolosin JD. Gastrointestinal complications of diabetes. Endocrinol Metab Clin North Am 2013;42:809-32. [PMID: 24286951 DOI: 10.1016/j.ecl.2013.07.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mencin AA, Loomba R, Lavine JE. Caring for children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterol Hepatol 2015;12:617-28. [PMID: 26323878 DOI: 10.1038/nrgastro.2015.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
10 Chalasani N, Abdelmalek MF, Loomba R, Kowdley KV, McCullough AJ, Dasarathy S, Neuschwander-Tetri BA, Terrault N, Ferguson B, Shringarpure R, Shapiro D, Sanyal AJ. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. Liver Int 2019;39:924-32. [PMID: 30253043 DOI: 10.1111/liv.13974] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
11 Silva Figueiredo P, Inada AC, Ribeiro Fernandes M, Granja Arakaki D, Freitas KC, Avellaneda Guimarães RC, Aragão do Nascimento V, Aiko Hiane P. An Overview of Novel Dietary Supplements and Food Ingredients in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. Molecules 2018;23:E877. [PMID: 29641459 DOI: 10.3390/molecules23040877] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
12 de Oliveira PR, da Costa CA, de Bem GF, Cordeiro VS, Santos IB, de Carvalho LC, da Conceição EP, Lisboa PC, Ognibene DT, Sousa PJ, Martins GR, da Silva AJ, de Moura RS, Resende AC. Euterpe oleracea Mart.-Derived Polyphenols Protect Mice from Diet-Induced Obesity and Fatty Liver by Regulating Hepatic Lipogenesis and Cholesterol Excretion. PLoS One 2015;10:e0143721. [PMID: 26630290 DOI: 10.1371/journal.pone.0143721] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
13 Schwabe RF, Luedde T. Apoptosis and necroptosis in the liver: A matter of life and death. Nat Rev Gastroenterol Hepatol. 2018;15:738-752. [PMID: 30250076 DOI: 10.1038/s41575-018-0065-y] [Cited by in Crossref: 132] [Cited by in F6Publishing: 128] [Article Influence: 66.0] [Reference Citation Analysis]
14 Takaki A, Yamamoto K. Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful? World J Hepatol 2015; 7(7): 968-979 [PMID: 25954479 DOI: 10.4254/wjh.v7.i7.968] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 9.7] [Reference Citation Analysis]
15 Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017;177:633-640. [PMID: 28241279 DOI: 10.1001/jamainternmed.2016.9607] [Cited by in Crossref: 151] [Cited by in F6Publishing: 143] [Article Influence: 37.8] [Reference Citation Analysis]
16 Cheng HS, Tan WR, Low ZS, Marvalim C, Lee JYH, Tan NS. Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. Int J Mol Sci. 2019;20. [PMID: 31614690 DOI: 10.3390/ijms20205055] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 23.0] [Reference Citation Analysis]
17 Francque SM. The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease. Eur Cardiol 2014;9:10-5. [PMID: 30310479 DOI: 10.15420/ecr.2014.9.1.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
18 Dasarathy J, Varghese R, Feldman A, Khiyami A, McCullough AJ, Dasarathy S. Patients with Nonalcoholic Fatty Liver Disease Have a Low Response Rate to Vitamin D Supplementation. J Nutr 2017;147:1938-46. [PMID: 28814531 DOI: 10.3945/jn.117.254292] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
19 Cheng X, Yamauchi J, Lee S, Zhang T, Gong Z, Muzumdar R, Qu S, Dong HH. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice. J Biol Chem. 2017;292:3692-3705. [PMID: 28115523 DOI: 10.1074/jbc.m116.765917] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
20 Grander C, Grabherr F, Moschen AR, Tilg H. Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome. Visc Med 2016;32:329-34. [PMID: 27921044 DOI: 10.1159/000448940] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
21 Sumi T, Shirakami Y, Shimizu M, Kochi T, Ohno T, Kubota M, Shiraki M, Tsurumi H, Tanaka T, Moriwaki H. (-)-Epigallocatechin-3-gallate suppresses hepatic preneoplastic lesions developed in a novel rat model of non-alcoholic steatohepatitis. Springerplus 2013;2:690. [PMID: 25674420 DOI: 10.1186/2193-1801-2-690] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
22 Sepulveda-Crespo D, Resino S, Martinez I. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs 2021;81:419-43. [PMID: 33400242 DOI: 10.1007/s40265-020-01458-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol. 2011;4:391-417. [PMID: 22043231 DOI: 10.1177/1756283x11413002] [Cited by in Crossref: 141] [Cited by in F6Publishing: 71] [Article Influence: 14.1] [Reference Citation Analysis]
24 Attar BM, Van Thiel DH. Current concepts and management approaches in nonalcoholic fatty liver disease. ScientificWorldJournal. 2013;2013:481893. [PMID: 23576902 DOI: 10.1155/2013/481893] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
25 Sharma M, Premkumar M, Kulkarni AV, Kumar P, Reddy DN, Rao NP. Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. J Clin Transl Hepatol 2021;9:40-50. [PMID: 33604254 DOI: 10.14218/JCTH.2020.00055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Stradiot L, Mannaerts I, van Grunsven LA. P311, Friend, or Foe of Tissue Fibrosis? Front Pharmacol 2018;9:1151. [PMID: 30369881 DOI: 10.3389/fphar.2018.01151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Blaslov K, Bulum T, Zibar K, Duvnjak L. Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(23): 7356-7365 [PMID: 24966606 DOI: 10.3748/wjg.v20.i23.7356] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
28 Zelber-Sagi S, Ivancovsky-Wajcman D, Fliss-Isakov N, Hahn M, Webb M, Shibolet O, Kariv R, Tirosh O. Serum Malondialdehyde is Associated with Non-Alcoholic Fatty Liver and Related Liver Damage Differentially in Men and Women. Antioxidants (Basel) 2020;9:E578. [PMID: 32630732 DOI: 10.3390/antiox9070578] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
29 Lam S, Doran S, Yuksel HH, Altay O, Turkez H, Nielsen J, Boren J, Uhlen M, Mardinoglu A. Addressing the heterogeneity in liver diseases using biological networks. Brief Bioinform 2021;22:1751-66. [PMID: 32201876 DOI: 10.1093/bib/bbaa002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
30 Liu F, Bayliss G, Zhuang S. Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases. Clin Sci (Lond) 2019;133:1309-20. [PMID: 31217321 DOI: 10.1042/CS20190249] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
31 Dhaliwal HS, Singh R, Abraham AM, Sharma R, Goyal NK, Soloman R, Bansal P, Goyal A. Perception of Illness and Its Association with Treatment Willingness in Patients with Newly Diagnosed Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021. [PMID: 33409801 DOI: 10.1007/s10620-020-06794-2] [Reference Citation Analysis]
32 Brady GF, Kwan R, Ulintz PJ, Nguyen P, Bassirian S, Basrur V, Nesvizhskii AI, Loomba R, Omary MB. Nuclear lamina genetic variants, including a truncated LAP2, in twins and siblings with nonalcoholic fatty liver disease. Hepatology 2018;67:1710-25. [PMID: 28902428 DOI: 10.1002/hep.29522] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
33 Bloomgarden ZT. World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease: part 3. Diabetes Care 2011;34:e140-5. [PMID: 21868769 DOI: 10.2337/dc11-1027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Feng Q, Liu W, Baker SS, Li H, Chen C, Liu Q, Tang S, Guan L, Tsompana M, Kozielski R, Baker RD, Peng J, Liu P, Zhu R, Hu Y, Zhu L. Multi-targeting therapeutic mechanisms of the Chinese herbal medicine QHD in the treatment of non-alcoholic fatty liver disease. Oncotarget. 2017;8:27820-27838. [PMID: 28416740 DOI: 10.18632/oncotarget.15482] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
35 Saponaro C, Gaggini M, Gastaldelli A. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep. 2015;15:607. [PMID: 25894944 DOI: 10.1007/s11892-015-0607-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 10.2] [Reference Citation Analysis]
36 Brunner KT, Henneberg CJ, Wilechansky RM, Long MT. Nonalcoholic Fatty Liver Disease and Obesity Treatment. Curr Obes Rep 2019;8:220-8. [PMID: 30945129 DOI: 10.1007/s13679-019-00345-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 20.0] [Reference Citation Analysis]
37 Masri OA, Chalhoub JM, Sharara AI. Role of vitamins in gastrointestinal diseases. World J Gastroenterol 2015; 21(17): 5191-5209 [PMID: 25954093 DOI: 10.3748/wjg.v21.i17.5191] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
38 Yang ZR, Wang HF, Zuo TC, Guan LL, Dai N. Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats. BMC Pharmacol Toxicol 2016;17:16. [PMID: 27075663 DOI: 10.1186/s40360-016-0059-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
39 Cauchy F, Belghiti J. A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma. J Hepatocell Carcinoma 2015;2:19-27. [PMID: 27508191 DOI: 10.2147/JHC.S44521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Eshraghian A. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(42): 7495-7504 [PMID: 29204050 DOI: 10.3748/wjg.v23.i42.7495] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
41 Aly FZ, Kleiner DE. Update on fatty liver disease and steatohepatitis. Adv Anat Pathol 2011;18:294-300. [PMID: 21654360 DOI: 10.1097/PAP.0b013e318220f59b] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
42 Lu W, Li S, Li J, Wang J, Zhang R, Zhou Y, Yin Q, Zheng Y, Wang F, Xia Y, Chen K, Liu T, Lu J, Zhou Y, Guo C. Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Gastroenterol Res Pract 2016;2016:1459790. [PMID: 27651787 DOI: 10.1155/2016/1459790] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 9.2] [Reference Citation Analysis]
43 Erion DM, Park HJ, Lee HY. The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. BMB Rep. 2016;49:139-148. [PMID: 26728273 DOI: 10.5483/bmbrep.2016.49.3.268] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
44 Zhang L, Xu J, Song H, Yao Z, Ji G. Extracts from Salvia-Nelumbinis naturalis alleviate hepatosteatosis via improving hepatic insulin sensitivity. J Transl Med 2014;12:236. [PMID: 25160038 DOI: 10.1186/s12967-014-0236-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
45 Sundaram SS, Halbower A, Pan Z, Robbins K, Capocelli KE, Klawitter J, Shearn CT, Sokol RJ. Nocturnal hypoxia-induced oxidative stress promotes progression of pediatric non-alcoholic fatty liver disease. J Hepatol 2016;65:560-9. [PMID: 27501738 DOI: 10.1016/j.jhep.2016.04.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
46 Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, Fischer W, Steiner F, Lindauer E, Otto M, Dreyhaupt J, Grehl T, Hermann A, Winkler AS, Bogdahn U, Benecke R, Schrank B, Wessig C, Grosskreutz J, Ludolph AC; GERP ALS Study Group. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One 2012;7:e37885. [PMID: 22715372 DOI: 10.1371/journal.pone.0037885] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 10.1] [Reference Citation Analysis]
47 Cho MS, Kim SY, Suk KT, Kim BY. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol. 2018;56:855-867. [PMID: 30377993 DOI: 10.1007/s12275-018-8346-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
48 Sterling RK, Sanyal AJ. Pentoxifylline for steatohepatitis: magic bullet or smoking gun? Hepatology 2011;54:1496-9. [PMID: 22045667 DOI: 10.1002/hep.24612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
49 Souza-Mello V. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World J Hepatol 2015; 7(8): 1012-1019 [PMID: 26052390 DOI: 10.4254/wjh.v7.i8.1012] [Cited by in Crossref: 98] [Cited by in F6Publishing: 88] [Article Influence: 16.3] [Reference Citation Analysis]
50 Yang L, Lin W, Nugent CA, Hao S, Song H, Liu T, Zheng P. Lingguizhugan Decoction Protects against High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease by Alleviating Oxidative Stress and Activating Cholesterol Secretion. International Journal of Genomics 2017;2017:1-12. [DOI: 10.1155/2017/2790864] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
51 Barata L, Feitosa MF, Bielak LF, Halligan B, Baldridge AS, Guo X, Yerges-Armstrong LM, Smith AV, Yao J, Palmer ND, VanWagner LB, Carr JJ, Chen YI, Allison M, Budoff MJ, Handelman SK, Kardia SLR, Mosley TH Jr, Ryan K, Harris TB, Launer LJ, Gudnason V, Rotter JI, Fornage M, Rasmussen-Torvik LJ, Borecki IB, O'Connell JR, Peyser PA, Speliotes EK, Province MA. Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes. Hepatol Commun 2019;3:894-907. [PMID: 31334442 DOI: 10.1002/hep4.1353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
52 Kalogirou M, Sinakos E. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle? World J Hepatol 2018; 10(11): 790-794 [PMID: 30533179 DOI: 10.4254/wjh.v10.i11.790] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
53 Kalavalapalli S, Bril F, Koelmel JP, Abdo K, Guingab J, Andrews P, Li WY, Jose D, Yost RA, Frye RF, Garrett TJ, Cusi K, Sunny NE. Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. Am J Physiol Endocrinol Metab 2018;315:E163-73. [PMID: 29634314 DOI: 10.1152/ajpendo.00023.2018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
54 Bansal R, Nagórniewicz B, Prakash J. Clinical Advancements in the Targeted Therapies against Liver Fibrosis. Mediators Inflamm 2016;2016:7629724. [PMID: 27999454 DOI: 10.1155/2016/7629724] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 9.6] [Reference Citation Analysis]
55 Mattar RE, Al-alem F, Simoneau E, Hassanain M. Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection. World J Gastroenterol 2016; 22(2): 567-581 [PMID: 26811608 DOI: 10.3748/wjg.v22.i2.567] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
56 Wong C, Yaow CYL, Ng CH, Chin YH, Low YF, Lim AYL, Muthiah MD, Khoo CM. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis. Front Endocrinol (Lausanne) 2020;11:609135. [PMID: 33643221 DOI: 10.3389/fendo.2020.609135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
57 Kenerson HL, Yeh MM, Yeung RS. Tuberous sclerosis complex-1 deficiency attenuates diet-induced hepatic lipid accumulation. PLoS One 2011;6:e18075. [PMID: 21479224 DOI: 10.1371/journal.pone.0018075] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
58 Klaebel JH, Skjødt M, Skat-Rørdam J, Rakipovski G, Ipsen DH, Schou-Pedersen AMV, Lykkesfeldt J, Tveden-Nyborg P. Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model. Nutrients 2019;11:E2834. [PMID: 31752351 DOI: 10.3390/nu11112834] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
59 Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 2014; 20(10): 2515-2532 [PMID: 24627588 DOI: 10.3748/wjg.v20.i10.2515] [Cited by in CrossRef: 190] [Cited by in F6Publishing: 176] [Article Influence: 27.1] [Reference Citation Analysis]
60 Yoshino S, Iwasaki Y, Matsumoto S, Satoh T, Ozawa A, Yamada E, Kakizaki S, Trejo JAO, Uchiyama Y, Yamada M, Mori M. Administration of small-molecule guanabenz acetate attenuates fatty liver and hyperglycemia associated with obesity. Sci Rep 2020;10:13671. [PMID: 32792584 DOI: 10.1038/s41598-020-70689-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
61 Oliveira CP, de Lima Sanches P, de Abreu-Silva EO, Marcadenti A. Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease. J Diabetes Res. 2016;2016:4597246. [PMID: 26770987 DOI: 10.1155/2016/4597246] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
62 Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV; NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010;52:913-24. [PMID: 20648476 DOI: 10.1002/hep.23784] [Cited by in Crossref: 290] [Cited by in F6Publishing: 276] [Article Influence: 26.4] [Reference Citation Analysis]
63 Tsou P, Wu CJ. Serum Vitamin E Levels of Adults with Nonalcoholic Fatty Liver Disease: An Inverse Relationship with All-Cause Mortality in Non-Diabetic but Not in Pre-Diabetic or Diabetic Subjects. J Clin Med 2019;8:E1057. [PMID: 31330971 DOI: 10.3390/jcm8071057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
64 Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol 2018; 24(30): 3361-3373 [PMID: 30122876 DOI: 10.3748/wjg.v24.i30.3361] [Cited by in CrossRef: 159] [Cited by in F6Publishing: 131] [Article Influence: 53.0] [Reference Citation Analysis]
65 Goh GB, Pan A, Chow WC, Yuan JM, Koh WP. Association between diabetes mellitus and cirrhosis mortality: the Singapore Chinese Health Study. Liver Int. 2017;37:251-258. [PMID: 27566448 DOI: 10.1111/liv.13241] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
66 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Reference Citation Analysis]
67 Xu R, Zhang S, Tao A, Chen G, Zhang M. Influence of vitamin E supplementation on glycaemic control: a meta-analysis of randomised controlled trials. PLoS One 2014;9:e95008. [PMID: 24740143 DOI: 10.1371/journal.pone.0095008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
68 Magosso E, Ansari MA, Gopalan Y, Shuaib IL, Wong JW, Khan NA, Abu Bakar MR, Ng BH, Yuen KH. Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial. Nutr J. 2013;12:166. [PMID: 24373555 DOI: 10.1186/1475-2891-12-166] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
69 Violet PC, Ebenuwa IC, Wang Y, Niyyati M, Padayatty SJ, Head B, Wilkins K, Chung S, Thakur V, Ulatowski L, Atkinson J, Ghelfi M, Smith S, Tu H, Bobe G, Liu CY, Herion DW, Shamburek RD, Manor D, Traber MG, Levine M. Vitamin E sequestration by liver fat in humans. JCI Insight 2020;5:133309. [PMID: 31821172 DOI: 10.1172/jci.insight.133309] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
70 Ratziu V. Management of nonalcoholic steatohepatitis: Pharmacotherapy. Clin Liver Dis (Hoboken) 2012;1:122-4. [PMID: 31186867 DOI: 10.1002/cld.74] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Cho KY, Nakamura A, Omori K, Takase T, Miya A, Yamamoto K, Nomoto H, Kameda H, Taneda S, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. J Diabetes Investig 2021;12:1272-7. [PMID: 33131199 DOI: 10.1111/jdi.13457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 Morris EM, Rector RS, Thyfault JP, Ibdah JA. Mitochondria and redox signaling in steatohepatitis. Antioxid Redox Signal 2011;15:485-504. [PMID: 21128703 DOI: 10.1089/ars.2010.3795] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
73 Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;43:1109-23. [PMID: 27061197 DOI: 10.1111/apt.13620] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
74 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 9.4] [Reference Citation Analysis]
75 Alqahtani SA, Schattenberg JM. NAFLD in the Elderly. Clin Interv Aging 2021;16:1633-49. [PMID: 34548787 DOI: 10.2147/CIA.S295524] [Reference Citation Analysis]
76 Balaban YH. A key problem and challenge for hepatology: Obesity-related metabolic liver diseases. World J Hepatol 2011; 3(6): 142-146 [PMID: 21860673 DOI: 10.4254/wjh.v3.i6.142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
77 Honda Y, Kessoku T, Sumida Y, Kobayashi T, Kato T, Ogawa Y, Tomeno W, Imajo K, Fujita K, Yoneda M, Kataoka K, Taguri M, Yamanaka T, Seko Y, Tanaka S, Saito S, Ono M, Oeda S, Eguchi Y, Aoi W, Sato K, Itoh Y, Nakajima A. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterol 2017;17:96. [PMID: 28789631 DOI: 10.1186/s12876-017-0652-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
78 Kohli R, Myronovych A, Tan BK, Salazar-Gonzalez RM, Miles L, Zhang W, Oehrle M, Sandoval DA, Ryan KK, Seeley RJ, Setchell KD. Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH? Dig Dis 2015;33:440-6. [PMID: 26045281 DOI: 10.1159/000371699] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
79 Berardo C, Di Pasqua LG, Cagna M, Richelmi P, Vairetti M, Ferrigno A. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. Int J Mol Sci 2020;21:E9646. [PMID: 33348908 DOI: 10.3390/ijms21249646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
80 Xing B, Zhao Y, Dong B, Zhou Y, Lv W, Zhao W. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. J Diabetes Investig 2020;11:1238-47. [PMID: 32083798 DOI: 10.1111/jdi.13237] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 18.0] [Reference Citation Analysis]
81 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908-922. [PMID: 29967350 DOI: 10.1038/s41591-018-0104-9] [Cited by in Crossref: 777] [Cited by in F6Publishing: 742] [Article Influence: 259.0] [Reference Citation Analysis]
82 Kumar R, Rastogi A, Sharma MK, Bhatia V, Garg H, Bihari C, Sarin SK. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease? Indian J Endocrinol Metab. 2013;17:665-671. [PMID: 23961483 DOI: 10.4103/2230-8210.113758] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 7.4] [Reference Citation Analysis]
83 Jeong SW. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. Diabetes Metab J. 2020;44:640-657. [PMID: 33115209 DOI: 10.4093/dmj.2020.0115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
84 Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: Facts and figures. JHEP Rep 2019;1:468-79. [PMID: 32039399 DOI: 10.1016/j.jhepr.2019.10.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 17.0] [Reference Citation Analysis]
85 Seyedian SS, Hajiani E, Hashemi SJ, Masjedizadeh A, Shayesteh AA, Alavinejad P, Hormati A, Javaherforoushzadeh A, Khabazkhoob M. Relationship between serum ferritin level and transient elastography findings among patients with nonalcoholic fatty liver disease. J Family Med Prim Care 2017;6:750-4. [PMID: 29564257 DOI: 10.4103/jfmpc.jfmpc_158_17] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
86 Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Dig Dis Sci 2016;61:2108-17. [PMID: 26825843 DOI: 10.1007/s10620-016-4044-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
87 Cusi K. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia. 2016;59:1112-1120. [PMID: 27101131 DOI: 10.1007/s00125-016-3952-1] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 16.6] [Reference Citation Analysis]
88 Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012;56:943-51. [PMID: 22505194 DOI: 10.1002/hep.25772] [Cited by in Crossref: 261] [Cited by in F6Publishing: 259] [Article Influence: 29.0] [Reference Citation Analysis]
89 Völzke H. Multicausality in fatty liver disease: Is there a rationale to distinguish between alcoholic and non-alcoholic origin? World J Gastroenterol 2012; 18(27): 3492-3501 [PMID: 22826613 DOI: 10.3748/wjg.v18.i27.3492] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
90 Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, Portillo Romero J, Schmidt S, Chang KL, Samraj G, Malaty J, Huber K, Bedossa P, Kalavalapalli S, Marte J, Barb D, Poulton D, Fanous N, Cusi K. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care 2021;44:399-406. [PMID: 33355256 DOI: 10.2337/dc20-1997] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
91 Joshi-Barve S, Kirpich I, Cave MC, Marsano LS, McClain CJ. Alcoholic, Nonalcoholic, and Toxicant-Associated Steatohepatitis: Mechanistic Similarities and Differences. Cell Mol Gastroenterol Hepatol 2015;1:356-67. [PMID: 28210688 DOI: 10.1016/j.jcmgh.2015.05.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
92 Arriazu E, Ruiz de Galarreta M, Cubero FJ, Varela-Rey M, Pérez de Obanos MP, Leung TM, Lopategi A, Benedicto A, Abraham-Enachescu I, Nieto N. Extracellular matrix and liver disease. Antioxid Redox Signal 2014;21:1078-97. [PMID: 24219114 DOI: 10.1089/ars.2013.5697] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
93 Sumida Y, Shima T, Mitsumoto Y, Katayama T, Umemura A, Yamaguchi K, Itoh Y, Yoneda M, Okanoue T. Epidemiology: Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan. Int J Mol Sci 2020;21:E4337. [PMID: 32570776 DOI: 10.3390/ijms21124337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
94 Yan JK, Yan WH, Cai W. Fish oil-derived lipid emulsion induces RIP1-dependent and caspase 8-licensed necroptosis in IEC-6 cells through overproduction of reactive oxygen species. Lipids Health Dis 2018;17:148. [PMID: 29935529 DOI: 10.1186/s12944-018-0786-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
95 Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood). 2015;240:809-820. [PMID: 25873078 DOI: 10.1177/1535370215579161] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 9.5] [Reference Citation Analysis]
96 Yeo YH, Lai YC. Redox Regulation of Metabolic Syndrome: Recent Developments in Skeletal Muscle Insulin Resistance and Non-alcoholic Fatty Liver Disease (NAFLD). Curr Opin Physiol 2019;9:79-86. [PMID: 32818162 DOI: 10.1016/j.cophys.2019.05.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9:65-90. [PMID: 27055256 DOI: 10.1159/000443344] [Cited by in Crossref: 129] [Cited by in F6Publishing: 119] [Article Influence: 25.8] [Reference Citation Analysis]
98 Dichtel LE, Eajazi A, Miller KK, Torriani M, Bredella MA. Short- and Long-Term Reproducibility of Intrahepatic Lipid Quantification by 1H-MR Spectroscopy and CT in Obesity. J Comput Assist Tomogr 2016;40:678-82. [PMID: 27116479 DOI: 10.1097/RCT.0000000000000423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Wang YC, Kong WZ, Jin QM, Chen J, Dong L. Effects of salvianolic acid B on liver mitochondria of rats with nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(35): 10104-10112 [PMID: 26401075 DOI: 10.3748/wjg.v21.i35.10104] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
100 Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(47): 8263-8276 [PMID: 29307986 DOI: 10.3748/wjg.v23.i47.8263] [Cited by in CrossRef: 252] [Cited by in F6Publishing: 225] [Article Influence: 63.0] [Reference Citation Analysis]
101 Min HK, Maruyama H, Jang BK, Shimada M, Mirshahi F, Ren S, Oh Y, Puri P, Sanyal AJ. Suppression of IGF binding protein-3 by palmitate promotes hepatic inflammatory responses. FASEB J 2016;30:4071-82. [PMID: 27553225 DOI: 10.1096/fj.201600427R] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
102 Vuppalanchi R, Chalasani N. Screening Strategies for Nonalcoholic Steatohepatitis in High-Risk Individuals: Trimming Away the Fat. Dig Dis Sci. 2016;61:1790-1792. [PMID: 27010545 DOI: 10.1007/s10620-016-4134-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Andrews DB, Lavine JE. Medical therapy for nonalcoholic fatty liver disease in children and adolescents. Expert Rev Gastroenterol Hepatol 2012;6:1-3. [PMID: 22149573 DOI: 10.1586/egh.11.72] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
104 Bémeur C, Butterworth RF. Reprint of: Nutrition in the Management of Cirrhosis and its Neurological Complications. J Clin Exp Hepatol 2015;5:S131-40. [PMID: 26041952 DOI: 10.1016/j.jceh.2015.02.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
105 Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2015;17:500. [PMID: 25690590 DOI: 10.1007/s11883-015-0500-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 8.3] [Reference Citation Analysis]
106 Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1798-1810. [PMID: 27003600 DOI: 10.1053/j.gastro.2016.03.009] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 13.8] [Reference Citation Analysis]
107 Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, Dimick-Santos L, Friedman SL, Greene K, Kleiner DE, Megnien S, Neuschwander-Tetri BA, Ratziu V, Schabel E, Miller V, Sanyal AJ; Liver Forum Case Definitions Working Group. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology 2018;67:2001-12. [PMID: 29059456 DOI: 10.1002/hep.29607] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 21.0] [Reference Citation Analysis]
108 Tapper EB, Hunink MG, Afdhal NH, Lai M, Sengupta N. Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score. PLoS One 2016;11:e0147237. [PMID: 26905872 DOI: 10.1371/journal.pone.0147237] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
109 Huang YZ, Yang GY, Wang C, Chen XY, Zhang LL. Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis. World J Diabetes 2021; 12(9): 1576-1586 [PMID: 34630909 DOI: 10.4239/wjd.v12.i9.1576] [Reference Citation Analysis]
110 王素琴, 黄缘. 非酒精性脂肪肝病的研究进展. 世界华人消化杂志 2014; 22(23): 3410-3415 [DOI: 10.11569/wcjd.v22.i23.3410] [Reference Citation Analysis]
111 Hoang SA, Oseini A, Feaver RE, Cole BK, Asgharpour A, Vincent R, Siddiqui M, Lawson MJ, Day NC, Taylor JM, Wamhoff BR, Mirshahi F, Contos MJ, Idowu M, Sanyal AJ. Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease. Sci Rep 2019;9:12541. [PMID: 31467298 DOI: 10.1038/s41598-019-48746-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
112 Takeshita Y, Kanamori T, Tanaka T, Kaikoi Y, Kita Y, Takata N, Iida N, Arai K, Yamashita T, Harada K, Gabata T, Nakamura H, Kaneko S, Takamura T. Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Diabetes Ther 2020;11:549-60. [PMID: 31956961 DOI: 10.1007/s13300-020-00762-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Jung YK, Yim HJ. Reversal of liver cirrhosis: current evidence and expectations. Korean J Intern Med. 2017;32:213-228. [PMID: 28171717 DOI: 10.3904/kjim.2016.268] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 12.3] [Reference Citation Analysis]
114 Ferenci P. Silymarin in the treatment of liver diseases: What is the clinical evidence? Clin Liver Dis (Hoboken) 2016;7:8-10. [PMID: 31041017 DOI: 10.1002/cld.522] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
115 Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab 2020;42:101092. [PMID: 33010471 DOI: 10.1016/j.molmet.2020.101092] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 19.0] [Reference Citation Analysis]
116 Bémeur C, Butterworth RF. Nutrition in the management of cirrhosis and its neurological complications. J Clin Exp Hepatol 2014;4:141-50. [PMID: 25755550 DOI: 10.1016/j.jceh.2013.05.008] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 5.9] [Reference Citation Analysis]
117 Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed) 2021;26:206-37. [PMID: 33049668 DOI: 10.2741/4892] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
118 冷雪君, 颜学兵. 非酒精性脂肪性肝炎的药物治疗进展. 世界华人消化杂志 2017; 25(18): 1645-1654 [DOI: 10.11569/wcjd.v25.i18.1645] [Reference Citation Analysis]
119 Heritage M, Jaskowski L, Bridle K, Campbell C, Briskey D, Britton L, Fletcher L, Vitetta L, Subramaniam VN, Crawford D. Combination curcumin and vitamin E treatment attenuates diet-induced steatosis in Hfe-/- mice. World J Gastrointest Pathophysiol 2017; 8(2): 67-76 [PMID: 28573069 DOI: 10.4291/wjgp.v8.i2.67] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
120 Schiavo L, Busetto L, Cesaretti M, Zelber-Sagi S, Deutsch L, Iannelli A. Nutritional issues in patients with obesity and cirrhosis. World J Gastroenterol 2018; 24(30): 3330-3346 [PMID: 30122874 DOI: 10.3748/wjg.v24.i30.3330] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 21] [Article Influence: 10.3] [Reference Citation Analysis]
121 Bica C, Sandu C, Suceveanu AI, Sarbu E, Stoica RA, Gherghiceanu F, Bohiltea RE, Stefan SD, Stoian AP. Non-alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review). Exp Ther Med 2020;20:2387-91. [PMID: 32765720 DOI: 10.3892/etm.2020.8882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Curcic IB, Berkovic MC, Kuna L, Roguljic H, Smolic R, Varzic SC, Jukic LV, Smolic M. Obesity Paradox in Chronic Liver Diseases: Product of Bias or a Real Thing? J Clin Transl Hepatol. 2019;7:275-279. [PMID: 31608220 DOI: 10.14218/jcth.2019.00029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
123 McCommis KS, Finck BN. Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism. Cell Mol Gastroenterol Hepatol 2019;7:275-84. [PMID: 30686780 DOI: 10.1016/j.jcmgh.2018.09.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
124 Munteanu MA, Mircea PA. From NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome? Clujul Med 2014;87:80-6. [PMID: 26528002 DOI: 10.15386/cjmed-277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
125 Shojaie L, Iorga A, Dara L. Cell Death in Liver Diseases: A Review. Int J Mol Sci 2020;21:E9682. [PMID: 33353156 DOI: 10.3390/ijms21249682] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
126 Ma M, Duan R, Shen L, Liu M, Ji Y, Zhou H, Li C, Liang T, Li X, Guo L. The lncRNA Gm15622 stimulates SREBP-1c expression and hepatic lipid accumulation by sponging the miR-742-3p in mice. J Lipid Res 2020;61:1052-64. [PMID: 32229588 DOI: 10.1194/jlr.RA120000664] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
127 Chongmelaxme B, Phisalprapa P, Sawangjit R, Dilokthornsakul P, Chaiyakunapruk N. Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. Pharmacoeconomics 2019;37:267-78. [PMID: 30430467 DOI: 10.1007/s40273-018-0736-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
128 Dasarathy S, Dasarathy J, Khiyami A, Yerian L, Hawkins C, Sargent R, McCullough AJ. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2015;49:137-44. [PMID: 24583757 DOI: 10.1097/MCG.0000000000000099] [Cited by in Crossref: 99] [Cited by in F6Publishing: 47] [Article Influence: 16.5] [Reference Citation Analysis]
129 Zhu C, Kim K, Wang X, Bartolome A, Salomao M, Dongiovanni P, Meroni M, Graham MJ, Yates KP, Diehl AM, Schwabe RF, Tabas I, Valenti L, Lavine JE, Pajvani UB. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Sci Transl Med 2018;10:eaat0344. [PMID: 30463916 DOI: 10.1126/scitranslmed.aat0344] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 27.0] [Reference Citation Analysis]
130 Banini BA, Cazanave SC, Yates KP, Asgharpour A, Vincent R, Mirshahi F, Le P, Contos MJ, Tonascia J, Chalasani NP, Kowdley KV, McCullough AJ, Behling CA, Schwimmer JB, Lavine JE, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis. J Clin Gastroenterol 2019;53:750-8. [PMID: 30586008 DOI: 10.1097/MCG.0000000000001142] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
131 Depner CM, Torres-Gonzalez M, Tripathy S, Milne G, Jump DB. Menhaden oil decreases high-fat diet-induced markers of hepatic damage, steatosis, inflammation, and fibrosis in obese Ldlr-/- mice. J Nutr 2012;142:1495-503. [PMID: 22739374 DOI: 10.3945/jn.112.158865] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
132 Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18:599-612. [PMID: 33972770 DOI: 10.1038/s41575-021-00448-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
133 Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, Neuschwander-Tetri BA, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer JB, Lavine JE, Tonascia J, Chalasani N. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2121-30.e1-2. [PMID: 24846279 DOI: 10.1016/j.cgh.2014.05.010] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 9.3] [Reference Citation Analysis]
134 Asfari MM, Niyazi F, Lopez R, Dasarathy S, McCullough AJ. The association of nonalcoholic steatohepatitis and obstructive sleep apnea. Eur J Gastroenterol Hepatol 2017;29:1380-4. [PMID: 28914694 DOI: 10.1097/MEG.0000000000000973] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
135 Chang E, Park CY, Park SW. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J Diabetes Investig 2013;4:517-24. [PMID: 24843703 DOI: 10.1111/jdi.12107] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
136 Tsurusaki S, Tsuchiya Y, Koumura T, Nakasone M, Sakamoto T, Matsuoka M, Imai H, Yuet-Yin Kok C, Okochi H, Nakano H, Miyajima A, Tanaka M. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis. Cell Death Dis 2019;10:449. [PMID: 31209199 DOI: 10.1038/s41419-019-1678-y] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 30.0] [Reference Citation Analysis]
137 Chen G, Ni Y, Nagata N, Xu L, Ota T. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17:1379. [PMID: 27563875 DOI: 10.3390/ijms17091379] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
138 Xu L, Nagata N, Nagashimada M, Zhuge F, Ni Y, Chen G, Kamei J, Ishikawa H, Komatsu Y, Kaneko S, Ota T. A porcine placental extract prevents steatohepatitis by suppressing activation of macrophages and stellate cells in mice. Oncotarget 2018;9:15047-60. [PMID: 29599925 DOI: 10.18632/oncotarget.24587] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
139 Yoon IC, Eun JR. Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology. Yeungnam Univ J Med 2019;36:67-77. [PMID: 31620616 DOI: 10.12701/yujm.2019.00171] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
140 Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 2014;20:573-91. [PMID: 25242225 DOI: 10.1016/j.cmet.2014.08.005] [Cited by in Crossref: 269] [Cited by in F6Publishing: 249] [Article Influence: 38.4] [Reference Citation Analysis]
141 Sarna LK, Sid V, Wang P, Siow YL, House JD, O K. Tyrosol Attenuates High Fat Diet-Induced Hepatic Oxidative Stress: Potential Involvement of Cystathionine β-Synthase and Cystathionine γ-Lyase. Lipids 2016;51:583-90. [PMID: 26518313 DOI: 10.1007/s11745-015-4084-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
142 Lomonaco R, Chen J, Cusi K. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Ther Adv Endocrinol Metab. 2011;2:211-225. [PMID: 23148186 DOI: 10.1177/2042018811419157] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
143 Janczyk W, Socha P, Lebensztejn D, Wierzbicka A, Mazur A, Neuhoff-Murawska J, Matusik P. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC Pediatr. 2013;13:85. [PMID: 23702094 DOI: 10.1186/1471-2431-13-85] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
144 Huang S, Mu F, Li F, Wang W, Chen H, Lei L, Ma Y, Ding Y, Wang J. A Network-Based Approach to Explore the Mechanism and Bioactive Compounds of Erzhi Pill against Metabolic Dysfunction-Associated Fatty Liver Disease. J Diabetes Res 2020;2020:7867245. [PMID: 32724826 DOI: 10.1155/2020/7867245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Gupta V, Mah XJ, Garcia MC, Antonypillai C, van der Poorten D. Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21(37): 10621-10635 [PMID: 26457022 DOI: 10.3748/wjg.v21.i37.10621] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
146 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 61.0] [Reference Citation Analysis]
147 Soleimani D, Paknahad Z, Rouhani MH. Therapeutic Effects of Garlic on Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients: A Randomized Clinical Trial. Diabetes Metab Syndr Obes 2020;13:2389-97. [PMID: 32753923 DOI: 10.2147/DMSO.S254555] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
148 Kumar R, Mohan S. Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications. J Clin Transl Hepatol. 2017;5:216-223. [PMID: 28936403 DOI: 10.14218/jcth.2016.00068] [Cited by in Crossref: 17] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
149 Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Dig Dis Sci. 2015;60:3142-3148. [PMID: 26250831 DOI: 10.1007/s10620-015-3821-7] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 10.5] [Reference Citation Analysis]
150 Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology. Intern Med 2020;59:1931-7. [PMID: 32448832 DOI: 10.2169/internalmedicine.4398-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
151 Li J, Tuo B. Current and Emerging Approaches for Hepatic Fibrosis Treatment. Gastroenterol Res Pract 2021;2021:6612892. [PMID: 34326871 DOI: 10.1155/2021/6612892] [Reference Citation Analysis]
152 Rinella ME, Lominadze Z, Loomba R, Charlton M, Neuschwander-Tetri BA, Caldwell SH, Kowdley K, Harrison SA. Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therap Adv Gastroenterol 2016;9:4-12. [PMID: 26770262 DOI: 10.1177/1756283X15611581] [Cited by in Crossref: 38] [Cited by in F6Publishing: 13] [Article Influence: 7.6] [Reference Citation Analysis]
153 Egnatchik RA, Leamy AK, Jacobson DA, Shiota M, Young JD. ER calcium release promotes mitochondrial dysfunction and hepatic cell lipotoxicity in response to palmitate overload. Mol Metab. 2014;3:544-553. [PMID: 25061559 DOI: 10.1016/j.molmet.2014.05.004] [Cited by in Crossref: 103] [Cited by in F6Publishing: 96] [Article Influence: 14.7] [Reference Citation Analysis]
154 Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2013;14:20704-20728. [PMID: 24132155 DOI: 10.3390/ijms141020704] [Cited by in Crossref: 189] [Cited by in F6Publishing: 182] [Article Influence: 23.6] [Reference Citation Analysis]
155 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Pakravan H, Ahmadian M, Fani A, Aghaee D, Brumanad S, Pakzad B. The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. Adv Biomed Res 2017;6:40. [PMID: 28503495 DOI: 10.4103/2277-9175.204593] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
157 Caldwell S. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Clin Mol Hepatol 2017;23:103-8. [PMID: 28494529 DOI: 10.3350/cmh.2017.0103] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
158 Kwak KA, Cho HJ, Yang JY, Park YS. Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis. Can J Gastroenterol Hepatol. 2018;2018:4197857. [PMID: 29670867 DOI: 10.1155/2018/4197857] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
159 Sarwar R, Pierce N, Koppe S. Obesity and nonalcoholic fatty liver disease: current perspectives. Diabetes Metab Syndr Obes 2018;11:533-42. [PMID: 30288073 DOI: 10.2147/DMSO.S146339] [Cited by in Crossref: 62] [Cited by in F6Publishing: 41] [Article Influence: 20.7] [Reference Citation Analysis]
160 Marina A, von Frankenberg AD, Suvag S, Callahan HS, Kratz M, Richards TL, Utzschneider KM. Effects of dietary fat and saturated fat content on liver fat and markers of oxidative stress in overweight/obese men and women under weight-stable conditions. Nutrients. 2014;6:4678-4690. [PMID: 25353663 DOI: 10.3390/nu6114678] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
161 Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L; American Association for the Study of Liver Diseases; United States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61:1392-1405. [PMID: 25557690 DOI: 10.1002/hep.27678] [Cited by in Crossref: 213] [Cited by in F6Publishing: 194] [Article Influence: 35.5] [Reference Citation Analysis]
162 Krishnapuram R, Dhurandhar EJ, Dubuisson O, Kirk-Ballard H, Bajpeyi S, Butte N, Sothern MS, Larsen-Meyer E, Chalew S, Bennett B. Template to improve glycemic control without reducing adiposity or dietary fat. Am J Physiol Endocrinol Metab. 2011;300:E779-E789. [PMID: 21266671 DOI: 10.1152/ajpendo.00703.2010] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
163 Hunter H, de Gracia Hahn D, Duret A, Im YR, Cheah Q, Dong J, Fairey M, Hjalmarsson C, Li A, Lim HK, McKeown L, Mitrofan CG, Rao R, Utukuri M, Rowe IA, Mann JP. Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver. Elife 2020;9:e56573. [PMID: 33063664 DOI: 10.7554/eLife.56573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
164 Kulkarni S, Huang J, Tycksen E, Cliften PF, Rudnick DA. Diet Modifies Pioglitazone’s Influence on Hepatic PPAR γ -Regulated Mitochondrial Gene Expression. PPAR Research 2020;2020:1-20. [DOI: 10.1155/2020/3817573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
165 Kozyra M, Johansson I, Nordling Å, Ullah S, Lauschke VM, Ingelman-Sundberg M. Human hepatic 3D spheroids as a model for steatosis and insulin resistance. Sci Rep 2018;8:14297. [PMID: 30250238 DOI: 10.1038/s41598-018-32722-6] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 18.3] [Reference Citation Analysis]
166 Boeckmans J, Natale A, Rombaut M, Buyl K, Rogiers V, De Kock J, Vanhaecke T, M Rodrigues R. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. Cells 2019;9:E37. [PMID: 31877771 DOI: 10.3390/cells9010037] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
167 Traber MG, Mah E, Leonard SW, Bobe G, Bruno RS. Metabolic syndrome increases dietary α-tocopherol requirements as assessed using urinary and plasma vitamin E catabolites: a double-blind, crossover clinical trial. Am J Clin Nutr 2017;105:571-9. [PMID: 28077381 DOI: 10.3945/ajcn.116.138495] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
168 Liangpunsakul S, Chalasani N. What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol. 2012;107:976-978. [PMID: 22764020 DOI: 10.1038/ajg.2012.20] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 5.2] [Reference Citation Analysis]
169 Semmler G, Bachmayer S, Wernly S, Wernly B, Niederseer D, Huber-Schönauer U, Stickel F, Aigner E, Datz C. Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease. PLoS One 2020;15:e0244514. [PMID: 33382757 DOI: 10.1371/journal.pone.0244514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
170 Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(7): 1756-1767 [PMID: 24587653 DOI: 10.3748/wjg.v20.i7.1756] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
171 Harrison SA, Gunn N, Neff GW, Kohli A, Liu L, Flyer A, Goldkind L, Di Bisceglie AM. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nat Commun 2021;12:5503. [PMID: 34535644 DOI: 10.1038/s41467-021-25701-5] [Reference Citation Analysis]
172 Panasyuk G, Espeillac C, Chauvin C, Pradelli LA, Horie Y, Suzuki A, Annicotte JS, Fajas L, Foretz M, Verdeguer F, Pontoglio M, Ferré P, Scoazec JY, Birnbaum MJ, Ricci JE, Pende M. PPARγ contributes to PKM2 and HK2 expression in fatty liver. Nat Commun 2012;3:672. [PMID: 22334075 DOI: 10.1038/ncomms1667] [Cited by in Crossref: 96] [Cited by in F6Publishing: 94] [Article Influence: 10.7] [Reference Citation Analysis]
173 Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021;17:484-95. [PMID: 34131333 DOI: 10.1038/s41574-021-00507-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Snider NT, Weerasinghe SV, Singla A, Leonard JM, Hanada S, Andrews PC, Lok AS, Omary MB. Energy determinants GAPDH and NDPK act as genetic modifiers for hepatocyte inclusion formation. J Cell Biol 2011;195:217-29. [PMID: 22006949 DOI: 10.1083/jcb.201102142] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
175 Ziegler M, Wallert M, Lorkowski S, Peter K. Cardiovascular and Metabolic Protection by Vitamin E: A Matter of Treatment Strategy? Antioxidants (Basel) 2020;9:E935. [PMID: 33003543 DOI: 10.3390/antiox9100935] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
176 Nelson JE, Roth CL, Wilson LA, Yates KP, Aouizerat B, Morgan-Stevenson V, Whalen E, Hoofnagle A, Mason M, Gersuk V. Vitamin D Deficiency Is Associated with Increased Risk of Non-alcoholic Steatohepatitis in Adults with Non-alcoholic Fatty Liver Disease: Possible Role for MAPK and NF-kappaB? Am J Gastroenterol. 2016;111:852-863. [PMID: 27002799 DOI: 10.1038/ajg.2016.51] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 14.4] [Reference Citation Analysis]
177 Busso D, David A, Penailillo R, Echeverría G, Rigotti A, Kovalskys I, Gómez G, Cortés Sanabria LY, Yépez García MC, Pareja RG, Herrera-Cuenca M, Fisberg M, On Behalf Of The Elans Study Group. Intake of Vitamin E and C in Women of Reproductive Age: Results from the Latin American Study of Nutrition and Health (ELANS). Nutrients 2021;13:1954. [PMID: 34200192 DOI: 10.3390/nu13061954] [Reference Citation Analysis]
178 Jiang ZG, Robson SC, Yao Z. Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res. 2013;27:1-13. [PMID: 23554788 DOI: 10.7555/jbr.27.20120077] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
179 Kamata Y, Kessoku T, Shimizu T, Kobayashi T, Kurihashi T, Sato S, Kuraji S, Aoyama N, Iwasaki T, Takashiba S, Hamada N, Kodama T, Tamura T, Ino S, Higurashi T, Taguri M, Yamanaka T, Yoneda M, Usuda H, Wada K, Nakajima A, Minabe M. Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial. Trials 2020;21:291. [PMID: 32293522 DOI: 10.1186/s13063-020-4201-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
180 Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, Dhiman RK, Jayakumar RV, Madan K, Misra SP, Mishra H, Modi SK, Muruganathan A, Saboo B, Sahay R, Upadhyay R. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J ClinExpHepatol. 2015;5:51-68. [PMID: 25941433 DOI: 10.1016/j.jceh.2015.02.006] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 11.5] [Reference Citation Analysis]
181 Chen YY, Fang WH, Wang CC, Kao TW, Chang YW, Yang HF, Wu CJ, Sun YS, Chen WL. Increased body fat percentage in patients with hepatitis B and C virus infection. PLoS One 2018;13:e0200164. [PMID: 29965999 DOI: 10.1371/journal.pone.0200164] [Reference Citation Analysis]
182 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Reference Citation Analysis]
183 Corey KE, Vuppalanchi R. Assessment and management of comorbidities (including cardiovascular disease) in patients with nonalcoholic fatty liver disease. Clin Liver Dis (Hoboken) 2012;1:114-6. [PMID: 31186864 DOI: 10.1002/cld.26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
184 Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Hecht J, Tio F, Cusi K. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.J Clin Endocrinol Metab. 2017;102:2950-2961. [PMID: 28575232 DOI: 10.1210/jc.2017-00867] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
185 Verhaegen AA, Van Gaal LF. Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options. J Endocrinol Invest 2017;40:1165-74. [PMID: 28660606 DOI: 10.1007/s40618-017-0719-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
186 Kalhan SC, Edmison J, Marczewski S, Dasarathy S, Gruca LL, Bennett C, Duenas C, Lopez R. Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine. Clin Sci (Lond) 2011;121:179-89. [PMID: 21446920 DOI: 10.1042/CS20110060] [Cited by in Crossref: 45] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
187 Cho IJ, Oh DH, Yoo J, Hwang YC, Ahn KJ, Chung HY, Jeong SW, Moon JY, Lee SH, Lim SJ, Jeong IK. Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway. Sci Rep 2021;11:9894. [PMID: 33972568 DOI: 10.1038/s41598-021-88872-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(45): 16841-16857 [PMID: 25492998 DOI: 10.3748/wjg.v20.i45.16841] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
189 Finotti M, Romano M, Auricchio P, Scopelliti M, Brizzolari M, Grossi U, Piccino M, Benvenuti S, Morana G, Cillo U, Zanus G. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. J Pers Med 2021;11:499. [PMID: 34199535 DOI: 10.3390/jpm11060499] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
190 Parikh P, Ingle M, Patel J, Bhate P, Pandey V, Sawant P. An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients. Saudi J Gastroenterol. 2016;22:192-197. [PMID: 27184636 DOI: 10.4103/1319-3767.182451] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
191 Valenti L, Dongiovanni P, Fargion S. Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18(29): 3782-3786 [PMID: 22876027 DOI: 10.3748/wjg.v18.i29.3782] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
192 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol 2016; 7(2): 211-217 [PMID: 27190693 DOI: 10.4291/wjgp.v7.i2.211] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
193 Tanaka N, Aoyama T, Kimura S, Gonzalez FJ. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther. 2017;179:142-157. [PMID: 28546081 DOI: 10.1016/j.pharmthera.2017.05.011] [Cited by in Crossref: 97] [Cited by in F6Publishing: 94] [Article Influence: 24.3] [Reference Citation Analysis]
194 Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, Unalp-Arida A, Kowdley KV; Nonalcoholic Steatohepatitis Clinical Research Network. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology. 2011;53:448-457. [PMID: 21274866 DOI: 10.1002/hep.24038] [Cited by in Crossref: 171] [Cited by in F6Publishing: 159] [Article Influence: 15.5] [Reference Citation Analysis]
195 Kim KS, Lee BW. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:430-43. [PMID: 32791578 DOI: 10.3350/cmh.2020.0137] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
196 Alam S, Nazmul Hasan S, Mustafa G, Alam M, Kamal M, Ahmad N. Effect of Pentoxifylline on Histological Activity and Fibrosis of Nonalcoholic Steatohepatitis Patients: A One Year Randomized Control Trial. J Transl Int Med 2017;5:155-63. [PMID: 29085788 DOI: 10.1515/jtim-2017-0021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
197 Gupte AA, Liu JZ, Ren Y, Minze LJ, Wiles JR, Collins AR, Lyon CJ, Pratico D, Finegold MJ, Wong ST, Webb P, Baxter JD, Moore DD, Hsueh WA. Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. Hepatology 2010;52:2001-11. [PMID: 20938947 DOI: 10.1002/hep.23941] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 6.5] [Reference Citation Analysis]
198 Nelson JE, Brunt EM, Kowdley KV. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. Hepatology. 2012;56:1730-1740. [PMID: 22611049 DOI: 10.1002/hep.25856] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
199 Li M, Zhang S, Wu Y, Ye J, Cao X, Liu J, Sun Y, Zhong B. Prevalence of Insulin Resistance in Subjects with Nonalcoholic Fatty Liver Disease and Its Predictors in a Chinese Population. Dig Dis Sci 2015;60:2170-6. [PMID: 25686742 DOI: 10.1007/s10620-015-3564-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
200 Cunningham RP, Moore MP, Moore AN, Healy JC, Roberts MD, Rector RS, Martin JS. Curcumin supplementation mitigates NASH development and progression in female Wistar rats. Physiol Rep 2018;6:e13789. [PMID: 30009570 DOI: 10.14814/phy2.13789] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
201 Nam HH, Jun DW, Jeon HJ, Lee JS, Saeed WK, Kim EK. Osthol attenuates hepatic steatosis via decreased triglyceride synthesis not by insulin resistance. World J Gastroenterol 2014; 20(33): 11753-11761 [PMID: 25206279 DOI: 10.3748/wjg.v20.i33.11753] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
202 Schattenberg JM. Emerging Pharmacological Treatment in Nonalcoholic Steatohepatitis. Visc Med 2020;36:411-6. [PMID: 33251276 DOI: 10.1159/000507231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Lu D, Xia Q, Yang Z, Gao S, Sun S, Luo X, Li Z, Zhang X, Han S, Li X, Cao M. ENO3 promoted the progression of NASH by negatively regulating ferroptosis via elevation of GPX4 expression and lipid accumulation. Ann Transl Med 2021;9:661. [PMID: 33987359 DOI: 10.21037/atm-21-471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Arroyave-Ospina JC, Wu Z, Geng Y, Moshage H. Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy. Antioxidants (Basel) 2021;10:174. [PMID: 33530432 DOI: 10.3390/antiox10020174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
205 Nanthakumar CB, Hatley RJ, Lemma S, Gauldie J, Marshall RP, Macdonald SJ. Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat Rev Drug Discov. 2015;14:693-720. [PMID: 26338155 DOI: 10.1038/nrd4592] [Cited by in Crossref: 131] [Cited by in F6Publishing: 120] [Article Influence: 21.8] [Reference Citation Analysis]
206 Ismaiel A, Dumitraşcu DL. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Front Med (Lausanne) 2019;6:202. [PMID: 31616668 DOI: 10.3389/fmed.2019.00202] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 18.5] [Reference Citation Analysis]
207 Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-122. [PMID: 23363012 DOI: 10.1111/nyas.12016] [Cited by in Crossref: 159] [Cited by in F6Publishing: 148] [Article Influence: 19.9] [Reference Citation Analysis]
208 Frankel RA, Michels KA, Kim K, Kuhr DL, Omosigho UR, Wactawski-Wende J, Levine L, Perkins NJ, Mumford SL. Serum antioxidant vitamin concentrations and oxidative stress markers associated with symptoms and severity of premenstrual syndrome: a prospective cohort study. BMC Womens Health 2021;21:49. [PMID: 33530988 DOI: 10.1186/s12905-021-01187-7] [Reference Citation Analysis]
209 Lin SC, Ang B, Hernandez C, Bettencourt R, Jain R, Salotti J, Richards L, Kono Y, Bhatt A, Aryafar H. Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial. Therap Adv Gastroenterol. 2016;9:152-161. [PMID: 26929777 DOI: 10.1177/1756283x15621232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
210 Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut 2015;64:830-41. [PMID: 25681399 DOI: 10.1136/gutjnl-2014-306842] [Cited by in Crossref: 485] [Cited by in F6Publishing: 463] [Article Influence: 80.8] [Reference Citation Analysis]
211 Corey KE, Wilson LA, Altinbas A, Yates KP, Kleiner DE, Chung RT, Krauss RM, Chalasani N; NASH Clinical Research Network. Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial. Aliment Pharmacol Ther 2019;49:1205-13. [PMID: 30854694 DOI: 10.1111/apt.15216] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
212 de Meijer VE, Le HD, Meisel JA, Sharma AK, Popov Y, Puder M. Tumor necrosis factor α-converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice. PLoS One 2011;6:e25587. [PMID: 21980496 DOI: 10.1371/journal.pone.0025587] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
213 Mah E, Sapper TN, Chitchumroonchokchai C, Failla ML, Schill KE, Clinton SK, Bobe G, Traber MG, Bruno RS. α-Tocopherol bioavailability is lower in adults with metabolic syndrome regardless of dairy fat co-ingestion: a randomized, double-blind, crossover trial. Am J Clin Nutr 2015;102:1070-80. [PMID: 26447154 DOI: 10.3945/ajcn.115.118570] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
214 Wegermann K, Howe C, Henao R, Wang Y, Guy CD, Abdelmalek MF, Diehl AM, Moylan CA. Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver-Related Events in Nonalcoholic Fatty Liver Disease. Hepatol Commun 2021;5:608-17. [PMID: 33860119 DOI: 10.1002/hep4.1665] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Pan CS, Stanley TL. Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. Front Endocrinol (Lausanne) 2020;11:70. [PMID: 32153507 DOI: 10.3389/fendo.2020.00070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
216 Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. Front Pharmacol 2020;11:603926. [PMID: 33343375 DOI: 10.3389/fphar.2020.603926] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
217 Reimer KC, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int 2020;14:8-23. [PMID: 31802390 DOI: 10.1007/s12072-019-10001-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
218 Dinani A, Sanyal A. Nonalcoholic fatty liver disease: implications for cardiovascular risk. Cardiovasc Endocrinol 2017;6:62-72. [PMID: 31646122 DOI: 10.1097/XCE.0000000000000126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
219 Lakhani HV, Sharma D, Dodrill MW, Nawab A, Sharma N, Cottrill CL, Shapiro JI, Sodhi K. Phenotypic Alteration of Hepatocytes in Non-Alcoholic Fatty Liver Disease. Int J Med Sci 2018;15:1591-9. [PMID: 30588181 DOI: 10.7150/ijms.27953] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
220 Raphael BP, Duggan C. Prevention and treatment of intestinal failure-associated liver disease in children. Semin Liver Dis 2012;32:341-7. [PMID: 23397535 DOI: 10.1055/s-0032-1329903] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
221 Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2011;8:92-103. [PMID: 21912398 DOI: 10.1038/nrendo.2011.138] [Cited by in Crossref: 333] [Cited by in F6Publishing: 310] [Article Influence: 33.3] [Reference Citation Analysis]
222 Sorrentino G, Crispino P, Coppola D, De Stefano G. Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study. Drugs R D. 2015;15:21-25. [PMID: 25732561 DOI: 10.1007/s40268-015-0084-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
223 Koutoukidis DA, Morris E, Henry JA, Shammoon Y, Zimmerman M, Michalopoulou M, Jebb SA, Aveyard P. What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis. PLoS One 2021;16:e0250385. [PMID: 33882107 DOI: 10.1371/journal.pone.0250385] [Reference Citation Analysis]
224 Pais R, Maurel T. Natural History of NAFLD. J Clin Med 2021;10:1161. [PMID: 33802047 DOI: 10.3390/jcm10061161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
225 Stewart KE, Haller DL, Sargeant C, Levenson JL, Puri P, Sanyal AJ. Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models. Liver Int 2015;35:936-43. [PMID: 24521540 DOI: 10.1111/liv.12483] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
226 Chen C, Liu Q, Liu L, Hu YY, Feng Q. Potential Biological Effects of (-)-Epigallocatechin-3-gallate on the Treatment of Nonalcoholic Fatty Liver Disease. Mol Nutr Food Res 2018;62. [PMID: 28799714 DOI: 10.1002/mnfr.201700483] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
227 Amirinejad A, Totmaj AS, Mardali F, Hekmatdoost A, Emamat H, Safa M, Shidfar F. Administration of hydro-alcoholic extract of spinach improves oxidative stress and inflammation in high-fat diet-induced NAFLD rats. BMC Complement Med Ther 2021;21:221. [PMID: 34479550 DOI: 10.1186/s12906-021-03396-x] [Reference Citation Analysis]
228 Uchida D, Takaki A, Oyama A, Adachi T, Wada N, Onishi H, Okada H. Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma. Nutrients 2020;12:E1576. [PMID: 32481552 DOI: 10.3390/nu12061576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
229 Alferink LJM, Erler NS, de Knegt RJ, Janssen HLA, Metselaar HJ, Darwish Murad S, Kiefte-de Jong JC. Adherence to a plant-based, high-fibre dietary pattern is related to regression of non-alcoholic fatty liver disease in an elderly population. Eur J Epidemiol 2020;35:1069-85. [PMID: 32323115 DOI: 10.1007/s10654-020-00627-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
230 Athinarayanan S, Wei R, Zhang M, Bai S, Traber MG, Yates K, Cummings OW, Molleston J, Liu W, Chalasani N. Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials. PLoS One. 2014;9:e95366. [PMID: 24759732 DOI: 10.1371/journal.pone.0095366] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
231 Rao A, Kosters A, Mells JE, Zhang W, Setchell KD, Amanso AM, Wynn GM, Xu T, Keller BT, Yin H, Banton S, Jones DP, Wu H, Dawson PA, Karpen SJ. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci Transl Med 2016;8:357ra122. [PMID: 27655848 DOI: 10.1126/scitranslmed.aaf4823] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 21.5] [Reference Citation Analysis]
232 Abdelmalek MF. The clinical and economic burden of NAFLD: time to turn the tide. Nat Rev Gastroenterol Hepatol 2016;13:685-6. [DOI: 10.1038/nrgastro.2016.178] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
233 Kim H, Lee DS, An TH, Park HJ, Kim WK, Bae KH, Oh KJ. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. Int J Mol Sci 2021;22:4495. [PMID: 33925827 DOI: 10.3390/ijms22094495] [Reference Citation Analysis]
234 Marino L, Jornayvaz FR. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21(39): 11053-11076 [PMID: 26494962 DOI: 10.3748/wjg.v21.i39.11053] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
235 Legeza B, Marcolongo P, Gamberucci A, Varga V, Bánhegyi G, Benedetti A, Odermatt A. Fructose, Glucocorticoids and Adipose Tissue: Implications for the Metabolic Syndrome. Nutrients 2017;9:E426. [PMID: 28445389 DOI: 10.3390/nu9050426] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
236 Nakajima K. Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease. Int J Hepatol 2012;2012:950693. [PMID: 23304532 DOI: 10.1155/2012/950693] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
237 El Hadi H, Vettor R, Rossato M. Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth? Antioxidants (Basel) 2018;7:E12. [PMID: 29337849 DOI: 10.3390/antiox7010012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 14.0] [Reference Citation Analysis]
238 Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol. 2015;25:3282-3294. [PMID: 25994191 DOI: 10.1007/s00330-015-3731-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
239 Wang L, Zhu M, Cao L, Yao M, Lu Y, Wen X, Zhang Y, Ning J, Long H, Zhu Y, Hu G, Dang S, Fu Q, Chen L, Zhang X, Zhao J, Gao Z, Nan Y, Lu F. Liver Stiffness Measurement Can Reflect the Active Liver Necroinflammation in Population with Chronic Liver Disease: A Real-world Evidence Study. J Clin Transl Hepatol 2019;7:313-21. [PMID: 31915600 DOI: 10.14218/JCTH.2019.00040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
240 Vilar-Gomez E, Sookoian S, Pirola CJ, Liang T, Gawrieh S, Cummings O, Liu W, Chalasani NP. ADH1B∗2 Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption. Gastroenterology 2020;159:929-43. [PMID: 32454036 DOI: 10.1053/j.gastro.2020.05.054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
241 Ilan Y. Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment. Ann Gastroenterol 2018;31:296-304. [PMID: 29720855 DOI: 10.20524/aog.2018.0248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
242 Hardesty JE, Wahlang B, Falkner KC, Shi H, Jin J, Zhou Y, Wilkey DW, Merchant ML, Watson CT, Feng W, Morris AJ, Hennig B, Prough RA, Cave MC. Proteomic Analysis Reveals Novel Mechanisms by Which Polychlorinated Biphenyls Compromise the Liver Promoting Diet-Induced Steatohepatitis. J Proteome Res 2019;18:1582-94. [PMID: 30807179 DOI: 10.1021/acs.jproteome.8b00886] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
243 Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).J Diabetes Res. 2020;2020:3920196. [PMID: 32832560 DOI: 10.1155/2020/3920196] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
244 Vlaardingerbroek H, Ng K, Stoll B, Benight N, Chacko S, Kluijtmans LA, Kulik W, Squires EJ, Olutoye O, Schady D, Finegold ML, van Goudoever JB, Burrin DG. New generation lipid emulsions prevent PNALD in chronic parenterally fed preterm pigs. J Lipid Res 2014;55:466-77. [PMID: 24478031 DOI: 10.1194/jlr.M044545] [Cited by in Crossref: 59] [Cited by in F6Publishing: 22] [Article Influence: 8.4] [Reference Citation Analysis]
245 Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci 2018;75:3313-27. [PMID: 29936596 DOI: 10.1007/s00018-018-2860-6] [Cited by in Crossref: 234] [Cited by in F6Publishing: 231] [Article Influence: 78.0] [Reference Citation Analysis]
246 Alswat KA, Fallatah HI, Al-Judaibi B, Elsiesy HA, Al-Hamoudi WK, Qutub AN, Alturaify N, Al-Osaimi A. Position statement on the diagnosis and management of non-alcoholic fatty liver disease. Saudi Med J 2019;40:531-40. [PMID: 31219486 DOI: 10.15537/smj.2019.6.23980] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
247 Narayanan S, Surette FA, Hahn YS. The Immune Landscape in Nonalcoholic Steatohepatitis. Immune Netw 2016;16:147-58. [PMID: 27340383 DOI: 10.4110/in.2016.16.3.147] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
248 Shay JES, Hamilton JP. Hepatic fibrosis: Avenues of investigation and clinical implications. Clin Liver Dis (Hoboken) 2018;11:111-4. [PMID: 30992799 DOI: 10.1002/cld.702] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
249 Watanabe Y, Tsuchiya A, Terai S. The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future. Clin Mol Hepatol 2021;27:70-80. [PMID: 33317249 DOI: 10.3350/cmh.2020.0194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
250 Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs. 2013;73:1-14. [PMID: 23329465 DOI: 10.1007/s40265-012-0004-0] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 13.1] [Reference Citation Analysis]
251 Van Name MA, Savoye M, Chick JM, Galuppo BT, Feldstein AE, Pierpont B, Johnson C, Shabanova V, Ekong U, Valentino PL, Kim G, Caprio S, Santoro N. A Low ω-6 to ω-3 PUFA Ratio (n-6:n-3 PUFA) Diet to Treat Fatty Liver Disease in Obese Youth. J Nutr 2020;150:2314-21. [PMID: 32652034 DOI: 10.1093/jn/nxaa183] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
252 Abshagen K, Mense L, Fischer F, Liebig M, Schaeper U, Navarro G, Glass Ä, Frank M, Klöting N, Vollmar B. Repin1 deficiency in liver tissue alleviates NAFLD progression in mice. J Adv Res 2019;16:99-111. [PMID: 30899593 DOI: 10.1016/j.jare.2018.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
253 Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519-1523. [PMID: 21700865 DOI: 10.1126/science.1204265] [Cited by in Crossref: 1296] [Cited by in F6Publishing: 1266] [Article Influence: 129.6] [Reference Citation Analysis]
254 Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, Unalp-Arida A, Bass N;  Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Ethnicity and nonalcoholic fatty liver disease. Hepatology. 2012;55:769-780. [PMID: 21987488 DOI: 10.1002/hep.24726] [Cited by in Crossref: 130] [Cited by in F6Publishing: 125] [Article Influence: 14.4] [Reference Citation Analysis]
255 Feng Y, Chen Y, Yang B, Lan Q, Wang T, Cui G, Ren Z, Choi IC, Leung GP, Yan F, Chen D, Yu HH, Lee SMY. Hepatoprotective Effect of Jianpi Huoxue Formula on Nonalcoholic Fatty Liver Disease Induced by Methionine-Choline-Deficient Diet in Rat. Biomed Res Int 2019;2019:7465272. [PMID: 31355279 DOI: 10.1155/2019/7465272] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
256 Ni Y, Nagashimada M, Zhuge F, Zhan L, Nagata N, Tsutsui A, Nakanuma Y, Kaneko S, Ota T. Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: A comparison with vitamin E. Sci Rep. 2015;5:17192. [PMID: 26603489 DOI: 10.1038/srep17192] [Cited by in Crossref: 117] [Cited by in F6Publishing: 110] [Article Influence: 19.5] [Reference Citation Analysis]
257 Levine JA, Ann Lo A, Wallia A, Rogers M, VanWagner LB. Dapagliflozin-Induced Acute-on-Chronic Liver Injury. ACG Case Rep J 2016;3:e169. [PMID: 28008402 DOI: 10.14309/crj.2016.142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
258 Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 2020;111S:154299. [PMID: 32569680 DOI: 10.1016/j.metabol.2020.154299] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 17.0] [Reference Citation Analysis]
259 Stone RC, Chen V, Burgess J, Pannu S, Tomic-Canic M. Genomics of Human Fibrotic Diseases: Disordered Wound Healing Response. Int J Mol Sci 2020;21:E8590. [PMID: 33202590 DOI: 10.3390/ijms21228590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
260 Khodadoostan M, Zamanidoost M, Shavakhi A, Sanei H, Shahbazi M, Ahmadian M. Effects of Phlebotomy on Liver Enzymes and Histology of Patients with Nonalcoholic Fatty Liver Disease. Adv Biomed Res 2017;6:12. [PMID: 28299304 DOI: 10.4103/2277-9175.200787] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
261 Kelley CE, Brown AJ, Diehl AM, Setji TL. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol 2014; 20(39): 14172-14184 [PMID: 25339805 DOI: 10.3748/wjg.v20.i39.14172] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
262 Ajmera V, Belt P, Wilson LA, Gill RM, Loomba R, Kleiner DE, Neuschwander-Tetri BA, Terrault N; Nonalcoholic Steatohepatitis Clinical Research Network. Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. Clin Gastroenterol Hepatol 2018;16:1511-1520.e5. [PMID: 29378307 DOI: 10.1016/j.cgh.2018.01.026] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 15.7] [Reference Citation Analysis]
263 Wong CR, Lim JK. The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes: NAFLD and Cardiovascular Disease Outcomes. Clinical Liver Disease 2018;12:39-44. [DOI: 10.1002/cld.721] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
264 Gawrieh S, Guo X, Tan J, Lauzon M, Taylor KD, Loomba R, Cummings OW, Pillai S, Bhatnagar P, Kowdley KV, Yates K, Wilson LA, Chen YI, Rotter JI, Chalasani N; NASH Clinical Research Network. A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH. Hepatol Commun 2019;3:1571-84. [PMID: 31832568 DOI: 10.1002/hep4.1439] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
265 Jeong JY, Sohn JH, Baek YH, Cho YK, Kim Y, Kim H. New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial. World J Gastroenterol 2017; 23(32): 5977-5985 [PMID: 28932090 DOI: 10.3748/wjg.v23.i32.5977] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
266 Saponaro C, Gaggini M, Carli F, Gastaldelli A. The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. Nutrients 2015;7:9453-74. [PMID: 26580649 DOI: 10.3390/nu7115475] [Cited by in Crossref: 197] [Cited by in F6Publishing: 188] [Article Influence: 32.8] [Reference Citation Analysis]
267 Pappachan JM, Antonio FA, Edavalath M, Mukherjee A. Non-alcoholic fatty liver disease: a diabetologist’s perspective. Endocrine. 2014;45:344-353. [PMID: 24287794 DOI: 10.1007/s12020-013-0087-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
268 Ma Y, Belyaeva OV, Brown PM, Fujita K, Valles K, Karki S, de Boer YS, Koh C, Chen Y, Du X, Handelman SK, Chen V, Speliotes EK, Nestlerode C, Thomas E, Kleiner DE, Zmuda JM, Sanyal AJ, Kedishvili NY, Liang TJ, Rotman Y; (for the Nonalcoholic Steatohepatitis Clinical Research Network). 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. Hepatology 2019;69:1504-19. [PMID: 30415504 DOI: 10.1002/hep.30350] [Cited by in Crossref: 106] [Cited by in F6Publishing: 105] [Article Influence: 53.0] [Reference Citation Analysis]
269 van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H. The Effects of Physical Exercise on Fatty Liver Disease. Gene Expr 2018;18:89-101. [PMID: 29212576 DOI: 10.3727/105221617X15124844266408] [Cited by in Crossref: 79] [Cited by in F6Publishing: 46] [Article Influence: 19.8] [Reference Citation Analysis]
270 Ozaki A, Yoneda M, Kessoku T, Iwaki M, Kobayashi T, Honda Y, Ogawa Y, Imajo K, Sakai E, Taguri M, Yamanaka T, Iwasaki T, Kurihashi T, Saito S, Nakajima A. Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). Contemp Clin Trials Commun 2020;17:100516. [PMID: 31956725 DOI: 10.1016/j.conctc.2019.100516] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
271 Francque S, Vonghia L. Pharmacological Treatment for Non-alcoholic Fatty Liver Disease. Adv Ther 2019;36:1052-74. [PMID: 30888594 DOI: 10.1007/s12325-019-00898-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
272 Lin CW, Zhang H, Li M, Xiong X, Chen X, Chen X, Dong XC, Yin XM. Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice. J Hepatol. 2013;58:993-999. [PMID: 23339953 DOI: 10.1016/j.jhep.2013.01.011] [Cited by in Crossref: 233] [Cited by in F6Publishing: 237] [Article Influence: 29.1] [Reference Citation Analysis]
273 Wang Y, Vincent R, Yang J, Asgharpour A, Liang X, Idowu MO, Contos MJ, Daitya K, Siddiqui MS, Mirshahi F, Sanyal AJ. Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis. Hepatology 2017;65:1891-903. [PMID: 28133774 DOI: 10.1002/hep.29090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
274 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3478/wjg.v20.i7.1712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
275 Kawaguchi-Suzuki M, Cusi K, Bril F, Gong Y, Langaee T, Frye RF. A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. Front Pharmacol 2018;9:752. [PMID: 30065651 DOI: 10.3389/fphar.2018.00752] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
276 Cauchy F, Fuks D, Zarzavadjian Le Bian A, Belghiti J, Costi R. Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? World J Hepatol 2014; 6(5): 306-314 [PMID: 24868324 DOI: 10.4254/wjh.v6.i5.306] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
277 Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 2017;121:27-42. [PMID: 28506744 DOI: 10.1016/j.addr.2017.05.007] [Cited by in Crossref: 359] [Cited by in F6Publishing: 356] [Article Influence: 89.8] [Reference Citation Analysis]
278 Sao R, Aronow WS. Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Arch Med Sci 2018;14:1233-44. [PMID: 30393477 DOI: 10.5114/aoms.2017.68821] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
279 Miyazaki H, Takitani K, Koh M, Yoden A, Tamai H. The α-tocopherol status and expression of α-tocopherol-related proteins in methionine-choline deficient rats treated with vitamin E. J Clin Biochem Nutr 2014;54:190-7. [PMID: 24895482 DOI: 10.3164/jcbn.13-74] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
280 Fujimoto M, Tsuneyama K, Chen SY, Nishida T, Chen JL, Chen YC, Fujimoto T, Imura J, Shimada Y. Study of the effects of monacolin k and other constituents of red yeast rice on obesity, insulin-resistance, hyperlipidemia, and nonalcoholic steatohepatitis using a mouse model of metabolic syndrome. Evid Based Complement Alternat Med 2012;2012:892697. [PMID: 23320041 DOI: 10.1155/2012/892697] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
281 Kamada Y, Takahashi H, Shimizu M, Kawaguchi T, Sumida Y, Fujii H, Seko Y, Fukunishi S, Tokushige K, Nakajima A, Okanoue T; Japan Study Group of NAFLD (JSG‐NAFLD). Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review. J Gastroenterol 2021;56:1045-61. [PMID: 34718870 DOI: 10.1007/s00535-021-01833-9] [Reference Citation Analysis]
282 Ofosu A, Ramai D, Reddy M. Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. Ann Gastroenterol. 2018;31:288-295. [PMID: 29720854 DOI: 10.20524/aog.2018.0240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
283 Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014;147:765-783.e4. [PMID: 25046161 DOI: 10.1053/j.gastro.2014.07.018] [Cited by in Crossref: 365] [Cited by in F6Publishing: 350] [Article Influence: 52.1] [Reference Citation Analysis]
284 Nakano H, Wu S, Sakao K, Hara T, He J, Garcia S, Shetty K, Hou DX. Bilberry Anthocyanins Ameliorate NAFLD by Improving Dyslipidemia and Gut Microbiome Dysbiosis. Nutrients 2020;12:E3252. [PMID: 33114130 DOI: 10.3390/nu12113252] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
285 Alam S, Jahid Hasan M, Khan MAS, Alam M, Hasan N. Effect of Weight Reduction on Histological Activity and Fibrosis of Lean Nonalcoholic Steatohepatitis Patient. J Transl Int Med 2019;7:106-14. [PMID: 31637181 DOI: 10.2478/jtim-2019-0023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
286 Shiffman M, Freilich B, Vuppalanchi R, Watt K, Chan JL, Spada A, Hagerty DT, Schiff E. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2019;49:64-73. [PMID: 30430605 DOI: 10.1111/apt.15030] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 14.0] [Reference Citation Analysis]
287 Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism 2016;65:1049-61. [PMID: 26997538 DOI: 10.1016/j.metabol.2016.02.014] [Cited by in Crossref: 169] [Cited by in F6Publishing: 163] [Article Influence: 33.8] [Reference Citation Analysis]
288 García-Ruiz C, Fernández-Checa JC. Mitochondrial Oxidative Stress and Antioxidants Balance in Fatty Liver Disease. Hepatol Commun 2018;2:1425-39. [PMID: 30556032 DOI: 10.1002/hep4.1271] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 18.7] [Reference Citation Analysis]
289 Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53:362-376. [PMID: 29247356 DOI: 10.1007/s00535-017-1415-1] [Cited by in Crossref: 227] [Cited by in F6Publishing: 214] [Article Influence: 56.8] [Reference Citation Analysis]
290 Tien PC. Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy. Curr Atheroscler Rep 2015;17:73. [PMID: 26493063 DOI: 10.1007/s11883-015-0545-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
291 Galastri S, Zamara E, Milani S, Novo E, Provenzano A, Delogu W, Vizzutti F, Sutti S, Locatelli I, Navari N. Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. Clin Sci (Lond). 2012;123:459-471. [PMID: 22545719 DOI: 10.1042/cs20110515] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
292 Dai X, Feng J, Chen Y, Huang S, Shi X, Liu X, Sun Y. Traditional Chinese Medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Chin Med 2021;16:68. [PMID: 34344394 DOI: 10.1186/s13020-021-00469-4] [Reference Citation Analysis]
293 Machado MV, Kruger L, Jewell ML, Michelotti GA, Pereira Tde A, Xie G, Moylan CA, Diehl AM. Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model. Dig Dis Sci. 2016;61:137-148. [PMID: 26403427 DOI: 10.1007/s10620-015-3871-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
294 Chalasani N, Vuppalanchi R, Rinella M, Middleton MS, Siddiqui MS, Barritt AS 4th, Kolterman O, Flores O, Alonso C, Iruarrizaga-Lejarreta M, Gil-Redondo R, Sirlin CB, Zemel MB. Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018;47:1639-1651. [PMID: 29696666 DOI: 10.1111/apt.14674] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
295 Gusdon AM, Song KX, Qu S. Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev 2014;2014:637027. [PMID: 25371775 DOI: 10.1155/2014/637027] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 12.4] [Reference Citation Analysis]
296 Zhou C, Zhen M, Yu M, Li X, Yu T, Liu J, Jia W, Liu S, Li L, Li J, Sun Z, Zhao Z, Wang X, Zhang X, Wang C, Bai C. Gadofullerene inhibits the degradation of apolipoprotein B100 and boosts triglyceride transport for reversing hepatic steatosis. Sci Adv 2020;6:eabc1586. [PMID: 32917715 DOI: 10.1126/sciadv.abc1586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
297 Guthrie G, Burrin D. Impact of Parenteral Lipid Emulsion Components on Cholestatic Liver Disease in Neonates. Nutrients 2021;13:508. [PMID: 33557154 DOI: 10.3390/nu13020508] [Reference Citation Analysis]
298 Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother KI, von Schnurbein J, Sorkina E, Stanley T, Vigouroux C, Wabitsch M, Williams R, Yorifuji T. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab 2016;101:4500-11. [PMID: 27710244 DOI: 10.1210/jc.2016-2466] [Cited by in Crossref: 158] [Cited by in F6Publishing: 127] [Article Influence: 31.6] [Reference Citation Analysis]
299 Schlegel A. Studying non-alcoholic fatty liver disease with zebrafish: a confluence of optics, genetics, and physiology. Cell Mol Life Sci 2012;69:3953-61. [PMID: 22678663 DOI: 10.1007/s00018-012-1037-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
300 Samuel VT, Shulman GI. Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. Cell Metab 2018;27:22-41. [PMID: 28867301 DOI: 10.1016/j.cmet.2017.08.002] [Cited by in Crossref: 234] [Cited by in F6Publishing: 224] [Article Influence: 58.5] [Reference Citation Analysis]
301 Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World J Diabetes 2013; 4(3): 51-63 [PMID: 23772273 DOI: 10.4239/wjd.v4.i3.51] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 73] [Article Influence: 11.6] [Reference Citation Analysis]
302 Lambert JE, Parnell JA, Eksteen B, Raman M, Bomhof MR, Rioux KP, Madsen KL, Reimer RA. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol 2015;15:169. [PMID: 26635079 DOI: 10.1186/s12876-015-0400-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
303 Dokmak A, Almeqdadi M, Trivedi H, Krishnan S. Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease. World J Hepatol 2019; 11(7): 562-573 [PMID: 31388398 DOI: 10.4254/wjh.v11.i7.562] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
304 Arulanandan A, Loomba R. Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet? Curr Hepatol Rep 2015;14:109-18. [PMID: 26500833 DOI: 10.1007/s11901-015-0263-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
305 Yau H, Rivera K, Lomonaco R, Cusi K. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep. 2013;13:329-341. [PMID: 23625197 DOI: 10.1007/s11892-013-0378-8] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 8.6] [Reference Citation Analysis]
306 Chung W, Promrat K, Wands J. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World J Hepatol 2020; 12(9): 533-557 [PMID: 33033564 DOI: 10.4254/wjh.v12.i9.533] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
307 Li R, Bu Y, Yang C, Wang J. Effects of Lipid Deposition on Viscoelastic Response in Human Hepatic Cell Line HepG2. Front Physiol 2021;12:684121. [PMID: 34539426 DOI: 10.3389/fphys.2021.684121] [Reference Citation Analysis]
308 Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. Gut Liver. 2016;10:177-203. [PMID: 26934884 DOI: 10.5009/gnl15352] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 14.0] [Reference Citation Analysis]
309 Corey KE, Vuppalanchi R, Wilson LA, Cummings OW, Chalasani N; NASH CRN. NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels. Aliment Pharmacol Ther 2015;41:301-9. [PMID: 25429853 DOI: 10.1111/apt.13035] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
310 Décarie PO, Lepanto L, Billiard JS, Olivié D, Murphy-Lavallée J, Kauffmann C, Tang A. Fatty liver deposition and sparing: a pictorial review. Insights Imaging 2011;2:533-8. [PMID: 22347973 DOI: 10.1007/s13244-011-0112-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
311 Haus JM, Solomon TP, Kelly KR, Fealy CE, Kullman EL, Scelsi AR, Lu L, Pagadala MR, McCullough AJ, Flask CA. Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2013;98:E1181-E1188. [PMID: 23616151 DOI: 10.1210/jc.2013-1229] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
312 Miyazaki T, Shirakami Y, Kubota M, Ideta T, Kochi T, Sakai H, Tanaka T, Moriwaki H, Shimizu M. Sodium alginate prevents progression of non-alcoholic steatohepatitis and liver carcinogenesis in obese and diabetic mice. Oncotarget 2016;7:10448-58. [PMID: 26871288 DOI: 10.18632/oncotarget.7249] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
313 Noureddin M, Muthiah MD, Sanyal AJ. Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00105. [PMID: 33102791 DOI: 10.1002/edm2.105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
314 Dichtel LE, Corey KE, Misdraji J, Bredella MA, Schorr M, Osganian SA, Young BJ, Sung JC, Miller KK. The Association Between IGF-1 Levels and the Histologic Severity of Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2017;8:e217. [PMID: 28125073 DOI: 10.1038/ctg.2016.72] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
315 Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013;178:38-45. [PMID: 23703888 DOI: 10.1093/aje/kws448] [Cited by in Crossref: 506] [Cited by in F6Publishing: 471] [Article Influence: 63.3] [Reference Citation Analysis]
316 Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956-65. [PMID: 25468160 DOI: 10.1016/S0140-6736(14)61933-4] [Cited by in Crossref: 1241] [Cited by in F6Publishing: 624] [Article Influence: 177.3] [Reference Citation Analysis]
317 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32-42. [PMID: 27729660 DOI: 10.1038/nrgastro.2016.147] [Cited by in Crossref: 329] [Cited by in F6Publishing: 309] [Article Influence: 65.8] [Reference Citation Analysis]
318 Kobayashi Y, Tatsumi H, Hattori M, Sugiyama H, Wada S, Kuwahata M, Tanaka S, Kanemasa K, Sumida Y, Naito Y, Fukui M, Kido Y. Comparisons of dietary intake in Japanese with non-alcoholic fatty liver disease and type 2 diabetes mellitus. J Clin Biochem Nutr 2016;59:215-9. [PMID: 27895389 DOI: 10.3164/jcbn.16-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
319 Gawrieh S, Wilson LA, Cummings OW, Clark JM, Loomba R, Hameed B, Abdelmalek MF, Dasarathy S, Neuschwander-Tetri BA, Kowdley K, Kleiner D, Doo E, Tonascia J, Sanyal A, Chalasani N; NASH Clinical Research Network. Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. Am J Gastroenterol 2019;114:1626-35. [PMID: 31517638 DOI: 10.14309/ajg.0000000000000388] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 28.0] [Reference Citation Analysis]
320 Okamura K, Shirai K, Miyazaki M, Okuda T, Takamiya Y, Goto M, Urata H. Investigation of a Dipeptidyl Peptidase-4 Inhibitor/Thiazolidinedione Combination Drug for Patients With Type 2 Diabetes and Poor Glycemic Control: Difficulty With Patient Enrollment. J Clin Med Res 2019;11:89-97. [PMID: 30701000 DOI: 10.14740/jocmr3558] [Reference Citation Analysis]
321 Suzuki S, Fujita N, Hosogane N, Watanabe K, Ishii K, Toyama Y, Takubo K, Horiuchi K, Miyamoto T, Nakamura M, Matsumoto M. Excessive reactive oxygen species are therapeutic targets for intervertebral disc degeneration. Arthritis Res Ther 2015;17:316. [PMID: 26542776 DOI: 10.1186/s13075-015-0834-8] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 14.5] [Reference Citation Analysis]
322 Wahlang B, Prough RA, Falkner KC, Hardesty JE, Song M, Clair HB, Clark BJ, States JC, Arteel GE, Cave MC. Polychlorinated Biphenyl-Xenobiotic Nuclear Receptor Interactions Regulate Energy Metabolism, Behavior, and Inflammation in Non-alcoholic-Steatohepatitis. Toxicol Sci 2016;149:396-410. [PMID: 26612838 DOI: 10.1093/toxsci/kfv250] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
323 Milic S, Mikolasevic I, Krznaric-Zrnic I, Stanic M, Poropat G, Stimac D, Vlahovic-Palcevski V, Orlic L. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Des Devel Ther 2015;9:4835-45. [PMID: 26316717 DOI: 10.2147/DDDT.S64877] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
324 Le TA, Loomba R. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. J Clin Exp Hepatol 2012;2:156-73. [PMID: 25755424 DOI: 10.1016/S0973-6883(12)60104-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
325 Leamy AK, Egnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res 2013;52:165-74. [PMID: 23178552 DOI: 10.1016/j.plipres.2012.10.004] [Cited by in Crossref: 232] [Cited by in F6Publishing: 231] [Article Influence: 25.8] [Reference Citation Analysis]
326 Jin M, Niu X, Liu Y, Zhang D, Yuan D, Shen H. Effect of glucagon-like peptide-1 receptor agonists on adipokine level of nonalcoholic fatty liver disease in rats fed high-fat diet. Open Med (Wars) 2020;15:689-96. [PMID: 33336025 DOI: 10.1515/med-2020-0212] [Reference Citation Analysis]
327 Perakakis N, Joshi A, Peradze N, Stefanakis K, Li G, Feigh M, Veidal SS, Rosen G, Fleming M, Mantzoros CS. The Selective Peroxisome Proliferator-Activated Receptor Gamma Modulator CHS-131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis. Hepatol Commun 2020;4:1302-15. [PMID: 32923834 DOI: 10.1002/hep4.1558] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
328 Okazaki I, Noro T, Tsutsui N, Yamanouchi E, Kuroda H, Nakano M, Yokomori H, Inagaki Y. Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs). Cancers (Basel). 2014;6:1220-1255. [PMID: 24978432 DOI: 10.3390/cancers6031220] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
329 Patel P, Muller C, Paul S. Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis. World J Hepatol 2020; 12(8): 506-518 [PMID: 32952877 DOI: 10.4254/wjh.v12.i8.506] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
330 Vilar-Gomez E, Pirola CJ, Sookoian S, Wilson LA, Liang T, Chalasani N. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD. Clin Transl Gastroenterol 2021;12:e00400. [PMID: 34506332 DOI: 10.14309/ctg.0000000000000400] [Reference Citation Analysis]
331 Rockey DC. Fibrosis reversal after hepatitis C virus elimination. Curr Opin Gastroenterol. 2019;35:137-144. [PMID: 30865043 DOI: 10.1097/mog.0000000000000524] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 17.0] [Reference Citation Analysis]
332 Townsend SA, Newsome PN. Non-alcoholic fatty liver disease in 2016. Br Med Bull 2016;119:143-56. [PMID: 27543499 DOI: 10.1093/bmb/ldw031] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 9.2] [Reference Citation Analysis]
333 Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J; Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN). Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013;38:134-143. [PMID: 23718573 DOI: 10.1111/apt.12352] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 14.1] [Reference Citation Analysis]
334 Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE; NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55:77-85. [PMID: 21953442 DOI: 10.1002/hep.24706] [Cited by in Crossref: 260] [Cited by in F6Publishing: 242] [Article Influence: 26.0] [Reference Citation Analysis]
335 Ferro D, Baratta F, Pastori D, Cocomello N, Colantoni A, Angelico F, Del Ben M. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients 2020;12:E2762. [PMID: 32927776 DOI: 10.3390/nu12092762] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
336 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
337 Dubois V, Eeckhoute J, Lefebvre P, Staels B. Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J Clin Invest 2017;127:1202-14. [PMID: 28368286 DOI: 10.1172/JCI88894] [Cited by in Crossref: 142] [Cited by in F6Publishing: 72] [Article Influence: 35.5] [Reference Citation Analysis]
338 Rockey DC. Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies. Clin Gastroenterol Hepatol. 2013;11:224-31.e1-5. [PMID: 23305825 DOI: 10.1016/j.cgh.2013.01.005] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 7.1] [Reference Citation Analysis]
339 Siddiqui MS, Yamada G, Vuppalanchi R, Van Natta M, Loomba R, Guy C, Brandman D, Tonascia J, Chalasani N, Neuschwander-Tetri B, Sanyal AJ; NASH Clinical Research Network. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. Clin Gastroenterol Hepatol 2019;17:1877-1885.e5. [PMID: 30616027 DOI: 10.1016/j.cgh.2018.12.031] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 23.5] [Reference Citation Analysis]
340 Siddique A, Nelson JE, Aouizerat B, Yeh MM, Kowdley KV; NASH Clinical Research Network. Iron deficiency in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, and low serum hepcidin. Clin Gastroenterol Hepatol. 2014;12:1170-1178. [PMID: 24269922 DOI: 10.1016/j.cgh.2013.11.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
341 Podszun MC, Chung JY, Ylaya K, Kleiner DE, Hewitt SM, Rotman Y. 4-HNE Immunohistochemistry and Image Analysis for Detection of Lipid Peroxidation in Human Liver Samples Using Vitamin E Treatment in NAFLD as a Proof of Concept. J Histochem Cytochem 2020;68:635-43. [PMID: 32867573 DOI: 10.1369/0022155420946402] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
342 Takaki A, Kawai D, Yamamoto K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2014;15:7352-7379. [PMID: 24786095 DOI: 10.3390/ijms15057352] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 11.3] [Reference Citation Analysis]
343 Ben MD, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F. Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(26): 8341-8350 [PMID: 25024593 DOI: 10.3748/wjg.v20.i26.8341] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
344 Gitto S, Vitale G, Villa E, Andreone P. Treatment of nonalcoholic steatohepatitis in adults: present and future. Gastroenterol Res Pract. 2015;2015:732870. [PMID: 25866507 DOI: 10.1155/2015/732870] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
345 Komolafe O, Buzzetti E, Linden A, Best LM, Madden AM, Roberts D, Chase TJ, Fritche D, Freeman SC, Cooper NJ, Sutton AJ, Milne EJ, Wright K, Pavlov CS, Davidson BR, Tsochatzis E, Gurusamy KS. Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. Cochrane Database Syst Rev 2021;7:CD013157. [PMID: 34280304 DOI: 10.1002/14651858.CD013157.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
346 Dixon ED, Nardo AD, Claudel T, Trauner M. The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD. Genes (Basel) 2021;12:645. [PMID: 33926085 DOI: 10.3390/genes12050645] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
347 Ohki T, Isogawa A, Toda N, Tagawa K. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors. Clin Drug Investig. 2016;36:313-319. [PMID: 26914659 DOI: 10.1007/s40261-016-0383-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
348 Lombardi R, Onali S, Thorburn D, Davidson BR, Gurusamy KS, Tsochatzis E. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011640. [PMID: 28358980 DOI: 10.1002/14651858.CD011640.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
349 Carnagarin R, Tan K, Adams L, Matthews VB, Kiuchi MG, Marisol Lugo Gavidia L, Lambert GW, Lambert EA, Herat LY, Schlaich MP. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-A Condition Associated with Heightened Sympathetic Activation. Int J Mol Sci 2021;22:4241. [PMID: 33921881 DOI: 10.3390/ijms22084241] [Reference Citation Analysis]
350 Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(39): 5919-5943 [PMID: 33132645 DOI: 10.3748/wjg.v26.i39.5919] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
351 Albhaisi S, Sanyal A. Recent advances in understanding and managing non-alcoholic fatty liver disease. F1000Res 2018;7:F1000 Faculty Rev-720. [PMID: 29946426 DOI: 10.12688/f1000research.14421.1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
352 Nseir W, Shalata A, Marmor A, Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci. 2011;56:3439-3449. [PMID: 21655948 DOI: 10.1007/s10620-011-1767-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 5.0] [Reference Citation Analysis]
353 Ji BY, You ZH, Jiang HJ, Guo ZH, Zheng K. Prediction of drug-target interactions from multi-molecular network based on LINE network representation method. J Transl Med 2020;18:347. [PMID: 32894154 DOI: 10.1186/s12967-020-02490-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
354 Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2021;18:373-92. [PMID: 33568794 DOI: 10.1038/s41575-020-00408-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
355 Kornek M, Lynch M, Mehta SH, Lai M, Exley M, Afdhal NH, Schuppan D. Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology 2012;143:448-58. [PMID: 22537612 DOI: 10.1053/j.gastro.2012.04.031] [Cited by in Crossref: 117] [Cited by in F6Publishing: 112] [Article Influence: 13.0] [Reference Citation Analysis]
356 Duan JY, Lin X, Xu F, Shan SK, Guo B, Li FX, Wang Y, Zheng MH, Xu QS, Lei LM, Ou-Yang WL, Wu YY, Tang KX, Yuan LQ. Ferroptosis and Its Potential Role in Metabolic Diseases: A Curse or Revitalization? Front Cell Dev Biol 2021;9:701788. [PMID: 34307381 DOI: 10.3389/fcell.2021.701788] [Reference Citation Analysis]
357 Chao CY, Battat R, Al Khoury A, Restellini S, Sebastiani G, Bessissow T. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. World J Gastroenterol 2016; 22(34): 7727-7734 [PMID: 27678354 DOI: 10.3748/wjg.v22.i34.7727] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
358 Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des. 2013;19:5250-5269. [PMID: 23394092 DOI: 10.2174/1381612811399990344] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
359 Middleton JP, Wiener RC, Barnes BH, Gurka MJ, DeBoer MD. Clinical features of pediatric nonalcoholic fatty liver disease: a need for increased awareness and a consensus for screening. Clin Pediatr (Phila) 2014;53:1318-25. [PMID: 24477713 DOI: 10.1177/0009922813520072] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
360 Day CP. Non-alcoholic fatty liver disease: a massive problem. Clin Med. 2011;11:176-178. [PMID: 21526706 DOI: 10.7861/clinmedicine.11-2-176] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 7.6] [Reference Citation Analysis]
361 Kumar DP, Caffrey R, Marioneaux J, Santhekadur PK, Bhat M, Alonso C, Koduru SV, Philip B, Jain MR, Giri SR, Bedossa P, Sanyal AJ. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. Sci Rep 2020;10:9330. [PMID: 32518275 DOI: 10.1038/s41598-020-66458-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
362 Maiwall R, Gupta M. Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation. Transl Gastroenterol Hepatol 2020;5:18. [PMID: 32258522 DOI: 10.21037/tgh.2019.10.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
363 Uchida D, Takaki A, Adachi T, Okada H. Beneficial and Paradoxical Roles of Anti-Oxidative Nutritional Support for Non-Alcoholic Fatty Liver Disease. Nutrients 2018;10:E977. [PMID: 30060482 DOI: 10.3390/nu10080977] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
364 Malhi H, Allen AM, Watt KD. Nonalcoholic fatty liver: optimizing pretransplant selection and posttransplant care to maximize survival. Curr Opin Organ Transplant. 2016;21:99-106. [PMID: 26825357 DOI: 10.1097/mot.0000000000000283] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
365 Wolf Greenstein A, Majumdar N, Yang P, Subbaiah PV, Kineman RD, Cordoba-Chacon J. Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice. J Endocrinol 2017;232:107-21. [PMID: 27799461 DOI: 10.1530/JOE-16-0447] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 6.6] [Reference Citation Analysis]
366 Gawrieh S, Marion MC, Komorowski R, Wallace J, Charlton M, Kissebah A, Langefeld CD, Olivier M. Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Dig Dis Sci. 2012;57:952-957. [PMID: 22160635 DOI: 10.1007/s10620-011-1994-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
367 Mouralidarane A, Lin CI, Suleyman N, Soeda J, Oben JA. Practical management of the increasing burden of non-alcoholic fatty liver disease. Frontline Gastroenterol 2010;1:149-55. [PMID: 28839568 DOI: 10.1136/fg.2009.000935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
368 Kwan HY, Niu X, Dai W, Tong T, Chao X, Su T, Chan CL, Lee KC, Fu X, Yi H. Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers. Sci Rep. 2015;5:9114. [PMID: 25766252 DOI: 10.1038/srep09114] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
369 Akuta N, Watanabe C, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H. Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies. Hepatol Commun. 2017;1:46-52. [PMID: 29404432 DOI: 10.1002/hep4.1019] [Cited by in Crossref: 49] [Cited by in F6Publishing: 58] [Article Influence: 12.3] [Reference Citation Analysis]
370 Burton BK, Deegan PB, Enns GM, Guardamagna O, Horslen S, Hovingh GK, Lobritto SJ, Malinova V, McLin VA, Raiman J, Di Rocco M, Santra S, Sharma R, Sykut-Cegielska J, Whitley CB, Eckert S, Valayannopoulos V, Quinn AG. Clinical Features of Lysosomal Acid Lipase Deficiency. J Pediatr Gastroenterol Nutr 2015;61:619-25. [PMID: 26252914 DOI: 10.1097/MPG.0000000000000935] [Cited by in Crossref: 60] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
371 Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver. 2012;6:149-171. [PMID: 22570745 DOI: 10.5009/gnl.2012.6.2.149] [Cited by in Crossref: 247] [Cited by in F6Publishing: 231] [Article Influence: 27.4] [Reference Citation Analysis]
372 Monsour HP Jr, Frenette CT, Wyne K. Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J 2012;8:21-5. [PMID: 23227282 DOI: 10.14797/mdcj-8-3-21] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
373 Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, Lehnert H. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012;33:812-41. [PMID: 22829562 DOI: 10.1210/er.2012-1003] [Cited by in Crossref: 153] [Cited by in F6Publishing: 136] [Article Influence: 17.0] [Reference Citation Analysis]
374 Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci. 2013;14:22933-22966. [PMID: 24264040 DOI: 10.3390/ijms141122933] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 7.8] [Reference Citation Analysis]
375 Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep 2019;1:312-28. [PMID: 32039382 DOI: 10.1016/j.jhepr.2019.07.002] [Cited by in Crossref: 81] [Cited by in F6Publishing: 65] [Article Influence: 40.5] [Reference Citation Analysis]
376 Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol 2014; 20(26): 8407-8415 [PMID: 25024598 DOI: 10.3748/wjg.v20.i26.8407] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 56] [Article Influence: 7.9] [Reference Citation Analysis]
377 Stine JG, Schreibman I, Navabi S, Kang M, Dahmus J, Soriano C, Rivas G, Hummer B, Beyer M, Tressler H, Kimball SR, Patterson AD, Schmitz K, Sciamanna C. Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH. Contemp Clin Trials Commun 2020;18:100560. [PMID: 32309672 DOI: 10.1016/j.conctc.2020.100560] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
378 Ni Y, Zhuge F, Nagashimada M, Ota T. Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis. Nutrients. 2016;8:pii: E391. [PMID: 27347998 DOI: 10.3390/nu8070391] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 8.8] [Reference Citation Analysis]
379 Bieghs V, van Gorp PJ, Walenbergh SM, Gijbels MJ, Verheyen F, Buurman WA, Briles DE, Hofker MH, Binder CJ, Shiri-Sverdlov R. Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology. 2012;56:894-903. [PMID: 22334337 DOI: 10.1002/hep.25660] [Cited by in Crossref: 63] [Cited by in F6Publishing: 68] [Article Influence: 7.0] [Reference Citation Analysis]
380 Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol 2021;18:73-91. [PMID: 33268887 DOI: 10.1038/s41423-020-00579-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
381 Loomba R, Sirlin CB, Ang B, Bettencourt R, Jain R, Salotti J, Soaft L, Hooker J, Kono Y, Bhatt A, Hernandez L, Nguyen P, Noureddin M, Haufe W, Hooker C, Yin M, Ehman R, Lin GY, Valasek MA, Brenner DA, Richards L; San Diego Integrated NAFLD Research Consortium (SINC). Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology. 2015;61:1239-1250. [PMID: 25482832 DOI: 10.1002/hep.27647] [Cited by in Crossref: 216] [Cited by in F6Publishing: 209] [Article Influence: 36.0] [Reference Citation Analysis]
382 Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, Sanyal AJ, Kowdley KV, Neuschwander-Tetri BA, Brunt EM. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology. 2012;56:1311-1318. [PMID: 22532269 DOI: 10.1002/hep.25805] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 7.1] [Reference Citation Analysis]
383 Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clin Med Insights Ther 2016;8:75-84. [PMID: 28670148 DOI: 10.4137/cmt.s18885] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
384 Arab JP, Candia R, Zapata R, Muñoz C, Arancibia JP, Poniachik J, Soza A, Fuster F, Brahm J, Sanhueza E, Contreras J, Cuellar MC, Arrese M, Riquelme A. Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review. World J Gastroenterol 2014; 20(34): 12182-12201 [PMID: 25232252 DOI: 10.3748/wjg.v20.i34.12182] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
385 Spengler EK, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc 2015;90:1233-46. [PMID: 26219858 DOI: 10.1016/j.mayocp.2015.06.013] [Cited by in Crossref: 127] [Cited by in F6Publishing: 112] [Article Influence: 21.2] [Reference Citation Analysis]
386 Montano-Loza AJ, Thandassery RB, Czaja AJ. Targeting Hepatic Fibrosis in Autoimmune Hepatitis. Dig Dis Sci. 2016;61:3118-3139. [PMID: 27435327 DOI: 10.1007/s10620-016-4254-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
387 Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. Int J Mol Sci 2021;22:2350. [PMID: 33652942 DOI: 10.3390/ijms22052350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
388 Iqbal U, Perumpail BJ, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. Judicious Use of Lipid Lowering Agents in the Management of NAFLD. Diseases 2018;6:E87. [PMID: 30249980 DOI: 10.3390/diseases6040087] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
389 Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines (Basel). 2019;6. [PMID: 30889791 DOI: 10.3390/medicines6010041] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
390 Waniek S, di Giuseppe R, Plachta-Danielzik S, Ratjen I, Jacobs G, Koch M, Borggrefe J, Both M, Müller HP, Kassubek J, Nöthlings U, Esatbeyoglu T, Schlesinger S, Rimbach G, Lieb W. Association of Vitamin E Levels with Metabolic Syndrome, and MRI-Derived Body Fat Volumes and Liver Fat Content. Nutrients 2017;9:E1143. [PMID: 29057829 DOI: 10.3390/nu9101143] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
391 Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, Tomeno W, Kato S, Mawatari H, Fujita K, Yoneda M, Saito S, Nakajima A. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS One. 2016;11:e0146337. [PMID: 26731267 DOI: 10.1371/journal.pone.0146337] [Cited by in Crossref: 98] [Cited by in F6Publishing: 84] [Article Influence: 19.6] [Reference Citation Analysis]
392 Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova EN, Vovk EI, Starostin KM. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia. BMJ Open Gastroenterol 2020;7:e000368. [PMID: 32337059 DOI: 10.1136/bmjgast-2019-000368] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
393 Gawrieh S, Chalasani N. Pharmacotherapy for Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015;35:338-48. [PMID: 26378648 DOI: 10.1055/s-0035-1562951] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
394 Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 2014;15:8591-638. [PMID: 24830559 DOI: 10.3390/ijms15058591] [Cited by in Crossref: 178] [Cited by in F6Publishing: 164] [Article Influence: 25.4] [Reference Citation Analysis]
395 Hannah WN, Harrison SA. Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1365-1374. [PMID: 27052013 DOI: 10.1007/s10620-016-4153-y] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 12.6] [Reference Citation Analysis]
396 Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J. Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. J Clin Transl Hepatol 2017;5:67-75. [PMID: 28507929 DOI: 10.14218/JCTH.2016.00061] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
397 Tanaka N, Kimura T, Fujimori N, Nagaya T, Komatsu M, Tanaka E. Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J Gastroenterol 2019; 25(2): 163-177 [PMID: 30670907 DOI: 10.3748/wjg.v25.i2.163] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 39] [Article Influence: 25.0] [Reference Citation Analysis]
398 Blazina I, Selph S. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. Syst Rev 2019;8:295. [PMID: 31783920 DOI: 10.1186/s13643-019-1200-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
399 He L, Liu X, Wang L, Yang Z. Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials. Medicine (Baltimore) 2016;95:e4947. [PMID: 27759627 DOI: 10.1097/MD.0000000000004947] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
400 Bozzetto L, Prinster A, Annuzzi G, Costagliola L, Mangione A, Vitelli A, Mazzarella R, Longobardo M, Mancini M, Vigorito C, Riccardi G, Rivellese AA. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care 2012;35:1429-35. [PMID: 22723581 DOI: 10.2337/dc12-0033] [Cited by in Crossref: 132] [Cited by in F6Publishing: 116] [Article Influence: 14.7] [Reference Citation Analysis]
401 Cynis H, Kehlen A, Haegele M, Hoffmann T, Heiser U, Fujii M, Shibazaki Y, Yoneyama H, Schilling S, Demuth HU. Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice. Int J Exp Pathol 2013;94:217-25. [PMID: 23560443 DOI: 10.1111/iep.12020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
402 Uppal V, Mansoor S, Furuya KN. Pediatric Non-alcoholic Fatty Liver Disease. Curr Gastroenterol Rep 2016;18:24. [PMID: 27086005 DOI: 10.1007/s11894-016-0498-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
403 Zhang Y, Bobe G, Miranda CL, Lowry MB, Hsu VL, Lohr CV, Wong CP, Jump DB, Robinson MM, Sharpton TJ, Maier CS, Stevens JF, Gombart AF. Tetrahydroxanthohumol, a xanthohumol derivative, attenuates high-fat diet-induced hepatic steatosis by antagonizing PPARγ. Elife 2021;10:e66398. [PMID: 34128467 DOI: 10.7554/eLife.66398] [Reference Citation Analysis]
404 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
405 Bhattacharya D, Basta B, Mato JM, Craig A, Fernández-Ramos D, Lopitz-Otsoa F, Tsvirkun D, Hayardeny L, Chandar V, Schwartz RE, Villanueva A, Friedman SL. Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. JHEP Rep 2021;3:100237. [PMID: 34151243 DOI: 10.1016/j.jhepr.2021.100237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
406 Gatselis NK, Ntaios G, Makaritsis K, Dalekos GN. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clin Exp Med. 2014;14:121-131. [PMID: 23292294 DOI: 10.1007/s10238-012-0227-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
407 Mavrogiannaki AN, Migdalis IN. Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. Int J Endocrinol. 2013;2013:450639. [PMID: 23653642 DOI: 10.1155/2013/450639] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
408 van den Hoek AM, Pieterman EJ, van der Hoorn JW, Iruarrizaga-Lejarreta M, Alonso C, Verschuren L, Skjæret T, Princen HMG, Fraser DA. Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice. Hepatol Commun 2020;4:193-207. [PMID: 32025605 DOI: 10.1002/hep4.1453] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
409 Fujimori N, Tanaka N, Kimura T, Sano K, Horiuchi A, Kato N, Takahashi Y, Kuribayashi N, Sugiura A, Yamazaki T, Joshita S, Umemura T, Matsumoto A, Tanaka E. Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus. Clin J Gastroenterol 2020;13:83-9. [PMID: 31292843 DOI: 10.1007/s12328-019-01018-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
410 Tarantino G. Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable? Hepat Mon. 2013;13:e7560. [PMID: 23610586 DOI: 10.5812/hepatmon.7560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
411 Svendsen P, Graversen JH, Etzerodt A, Hager H, Røge R, Grønbæk H, Christensen EI, Møller HJ, Vilstrup H, Moestrup SK. Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes. Mol Ther Methods Clin Dev 2017;4:50-61. [PMID: 28344991 DOI: 10.1016/j.omtm.2016.11.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
412 Oh H, Jun DW, Saeed WK, Nguyen MH. Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment. Clin Mol Hepatol. 2016;22:327-335. [PMID: 27729634 DOI: 10.3350/cmh.2016.0049] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
413 Miyashima Y, Shibata M, Honma Y, Matsuoka H, Hiura M, Abe S, Harada M. Severe Alcoholic Hepatitis Effectively Treated with Vitamin E as an Add-on to Corticosteroids. Intern Med 2017;56:3293-7. [PMID: 29021453 DOI: 10.2169/internalmedicine.8767-16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
414 Silva AKS, Peixoto CA. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation. Cell Mol Life Sci. 2018;75:2951-2961. [PMID: 29789866 DOI: 10.1007/s00018-018-2838-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
415 Prasun P, Ginevic I, Oishi K. Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol related liver disease. Transl Gastroenterol Hepatol 2021;6:4. [PMID: 33437892 DOI: 10.21037/tgh-20-125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
416 Bennett H, Troutman TD, Sakai M, Glass CK. Epigenetic Regulation of Kupffer Cell Function in Health and Disease. Front Immunol 2020;11:609618. [PMID: 33574817 DOI: 10.3389/fimmu.2020.609618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
417 Jorge JM, Golas A, Patel N, Gonzalvo JP, Murr MM. Management of nonalcoholic fatty liver disease and the role of bariatric surgery: a brief review for surgeons. Surg Obes Relat Dis 2020;16:699-703. [PMID: 32151552 DOI: 10.1016/j.soard.2020.01.028] [Reference Citation Analysis]
418 Vaidya B, Bhochhibhoya M, Nakarmi S. Efficacy of Vitamin E in Methotrexate-Induced Hepatotoxicity in Rheumatoid Arthritis : An Open-Label Case-Control Study.Int J Rheumatol. 2020;2020:5723485. [PMID: 32411250 DOI: 10.1155/2020/5723485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
419 Wang Z, Park H, Bae EJ. Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study. Korean J Physiol Pharmacol 2019;23:459-66. [PMID: 31680767 DOI: 10.4196/kjpp.2019.23.6.459] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
420 Jalili R, Somi MH, Hosseinifard H, Salehnia F, Ghojazadeh M, Makhdami N, Shirmohammadi M. The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. Adv Pharm Bull. 2020;10:542-555. [PMID: 33072533 DOI: 10.34172/apb.2020.065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
421 Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B, Doo E, Kleiner DE, Behling C, Loomba R; NASH CRN. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013;58:1644-1654. [PMID: 23686698 DOI: 10.1002/hep.26465] [Cited by in Crossref: 103] [Cited by in F6Publishing: 93] [Article Influence: 12.9] [Reference Citation Analysis]
422 Oniciu DC, Hashiguchi T, Shibazaki Y, Bisgaier CL. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH. PLoS One 2018;13:e0194568. [PMID: 29847555 DOI: 10.1371/journal.pone.0194568] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
423 Mukherjee S. Advances in the treatment of nonalcoholic steatohepatitis. World J Pharmacol 2020; 9(1): 1-12 [DOI: 10.5497/wjp.v9.i1.1] [Reference Citation Analysis]
424 Than NN, Newsome PN. Non-alcoholic fatty liver disease: when to intervene and with what. Clin Med (Lond) 2015;15:186-90. [PMID: 25824073 DOI: 10.7861/clinmedicine.15-2-186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
425 Gurka MJ, Mack JA, Chi X, DeBoer MD. Use of metabolic syndrome severity to assess treatment with vitamin E and pioglitazone for non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2021;36:249-56. [PMID: 32506513 DOI: 10.1111/jgh.15131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
426 Wieland AC, Quallick M, Truesdale A, Mettler P, Bambha KM. Identifying practice gaps to optimize medical care for patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2013;58:2809-2816. [PMID: 23843097 DOI: 10.1007/s10620-013-2740-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
427 Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659-1668. [PMID: 21521847 DOI: 10.1001/jama.2011.520.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
428 Sakitani K, Enooku K, Kubo H, Tanaka A, Arai H, Kawazu S, Koike K. Clinical characteristics of patients with diabetes mellitus and fatty liver diagnosed by liver/spleen Hounsfield units on CT scan. J Int Med Res 2017;45:1208-20. [PMID: 28553763 DOI: 10.1177/0300060517707672] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
429 Yu HH, Hsieh MC, Wu SY, Sy ED, Shan YS. Effects of duodenal-jejunal bypass surgery in ameliorating nonalcoholic steatohepatitis in diet-induced obese rats. Diabetes Metab Syndr Obes 2019;12:149-59. [PMID: 30705600 DOI: 10.2147/DMSO.S190631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
430 Peyrou M, Ramadori P, Bourgoin L, Foti M. PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs. PPAR Res 2012;2012:757803. [PMID: 23024649 DOI: 10.1155/2012/757803] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
431 Tucker RD, Ciofoaia V, Nadella S, Gay MD, Cao H, Huber M, Safronenka A, Shivapurkar N, Kallakury B, Kruger AJ, Kroemer AHK, Smith JP. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma. Dig Dis Sci 2020;65:189-203. [PMID: 31297627 DOI: 10.1007/s10620-019-05722-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
432 Gastaldelli A, Stefan N, Häring HU. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia 2021;64:1461-79. [PMID: 33877366 DOI: 10.1007/s00125-021-05442-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
433 Glass LM, Dickson RC, Anderson JC, Suriawinata AA, Putra J, Berk BS, Toor A. Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60:1024-1030. [PMID: 25354830 DOI: 10.1007/s10620-014-3380-3] [Cited by in Crossref: 80] [Cited by in F6Publishing: 66] [Article Influence: 11.4] [Reference Citation Analysis]
434 Depner CM, Traber MG, Bobe G, Kensicki E, Bohren KM, Milne G, Jump DB. A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/- mice. PLoS One. 2013;8:e83756. [PMID: 24358308 DOI: 10.1371/journal.pone.0083756] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
435 Abdel-Maboud M, Menshawy A, Menshawy E, Emara A, Alshandidy M, Eid M. The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Therap Adv Gastroenterol 2020;13:1756284820974917. [PMID: 33335561 DOI: 10.1177/1756284820974917] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
436 Alkhouri N, Tincopa M, Loomba R, Harrison SA. What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? Hepatol Commun 2021;5:1810-23. [PMID: 34499435 DOI: 10.1002/hep4.1814] [Reference Citation Analysis]
437 Malhotra N, Beaton MD. Management of non-alcoholic fatty liver disease in 2015. World J Hepatol 2015; 7(30): 2962-2967 [PMID: 26730275 DOI: 10.4254/wjh.v7.i30.2962] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
438 Klaebel JH, Rakipovski G, Andersen B, Lykkesfeldt J, Tveden-Nyborg P. Dietary Intervention Accelerates NASH Resolution Depending on Inflammatory Status with Minor Additive Effects on Hepatic Injury by Vitamin E Supplementation. Antioxidants (Basel) 2020;9:E808. [PMID: 32882802 DOI: 10.3390/antiox9090808] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
439 Hossain N, Kanwar P, Mohanty SR. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract 2016;2016:7109270. [PMID: 27006654 DOI: 10.1155/2016/7109270] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
440 Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Front Cardiovasc Med 2021;8:742382. [PMID: 34557535 DOI: 10.3389/fcvm.2021.742382] [Reference Citation Analysis]
441 Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15:45. [PMID: 28241825 DOI: 10.1186/s12916-017-0806-8] [Cited by in Crossref: 153] [Cited by in F6Publishing: 137] [Article Influence: 38.3] [Reference Citation Analysis]
442 Maréchal L, Laviolette M, Rodrigue-Way A, Sow B, Brochu M, Caron V, Tremblay A. The CD36-PPARγ Pathway in Metabolic Disorders. Int J Mol Sci 2018;19:E1529. [PMID: 29883404 DOI: 10.3390/ijms19051529] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 13.0] [Reference Citation Analysis]
443 Uhl P, Fricker G, Haberkorn U, Mier W. Current status in the therapy of liver diseases. Int J Mol Sci. 2014;15:7500-7512. [PMID: 24786290 DOI: 10.3390/ijms15057500] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
444 Yu Y, Cai J, She Z, Li H. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Adv Sci (Weinh). 2019;6:1801585. [PMID: 30828530 DOI: 10.1002/advs.201801585] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
445 Matthews L, Kleiner DE, Chairez C, McManus M, Nettles MJ, Zemanick K, Morse CG, Benator D, Kovacs JA, Hadigan C. Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. AIDS Res Hum Retroviruses. 2015;31:961-966. [PMID: 26214341 DOI: 10.1089/aid.2015.0093] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
446 Hugo SE, Cruz-Garcia L, Karanth S, Anderson RM, Stainier DY, Schlegel A. A monocarboxylate transporter required for hepatocyte secretion of ketone bodies during fasting. Genes Dev 2012;26:282-93. [PMID: 22302940 DOI: 10.1101/gad.180968.111] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 8.8] [Reference Citation Analysis]
447 Eslam M, George J. Genetic and epigenetic mechanisms of NASH. Hepatol Int 2016;10:394-406. [PMID: 26683320 DOI: 10.1007/s12072-015-9689-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
448 Pandyarajan V, Seki E. Nuclear Receptors: Opening Up New Avenues of Pediatric Fatty Liver Research. Hepatol Commun 2018;2:1157-9. [PMID: 30288469 DOI: 10.1002/hep4.1260] [Reference Citation Analysis]
449 Li H, Huang W, Wang M, Chen P, Chen L, Zhang X. Tandem Mass Tag-based quantitative proteomics analysis of metabolic associated fatty liver disease induced by high fat diet in mice. Nutr Metab (Lond) 2020;17:97. [PMID: 33292312 DOI: 10.1186/s12986-020-00522-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
450 Shamseddeen H, Vilar-Gomez E, Chalasani N, Myers RP, Subramanian GM, Shlevin HH, Allgood AE, Orman ES. Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring. Drug Saf 2020;43:281-90. [PMID: 31907854 DOI: 10.1007/s40264-019-00896-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
451 Karimian G, Kirschbaum M, Veldhuis ZJ, Bomfati F, Porte RJ, Lisman T. Vitamin E Attenuates the Progression of Non-Alcoholic Fatty Liver Disease Caused by Partial Hepatectomy in Mice. PLoS One 2015;10:e0143121. [PMID: 26600128 DOI: 10.1371/journal.pone.0143121] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
452 Cigrovski Berkovic M, Virovic-Jukic L, Bilic-Curcic I, Mrzljak A. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World J Gastroenterol 2020; 26(21): 2740-2757 [PMID: 32550751 DOI: 10.3748/wjg.v26.i21.2740] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
453 Michlin M, Argaev-Frenkel L, Weinstein-Fudim L, Ornoy A, Rosenzweig T. Maternal N-Acetyl Cysteine Intake Improved Glucose Tolerance in Obese Mice Offspring. Int J Mol Sci 2020;21:E1981. [PMID: 32183232 DOI: 10.3390/ijms21061981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
454 Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol 2020;6:9. [PMID: 32518675 DOI: 10.1186/s40842-020-00097-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
455 Petta S, Macaluso FS, Barcellona MR, Cammà C, Cabibi D, Di Marco V, Craxì A. Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. PLoS One. 2012;7:e51165. [PMID: 23227248 DOI: 10.1371/journal.pone.0051165] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
456 Bettermann K, Hohensee T, Haybaeck J. Steatosis and steatohepatitis: complex disorders. Int J Mol Sci. 2014;15:9924-9944. [PMID: 24897026 DOI: 10.3390/ijms15069924] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
457 van Welzen BJ, Mudrikova T, El Idrissi A, Hoepelman AIM, Arends JE. A review of Non-Alcoholic Fatty Liver Disease in HIV-infected patients: The next big thing? Infect Dis Ther. 2019;8:33-50. [PMID: 30607807 DOI: 10.1007/s40121-018-0229-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
458 Nelsen EM, Newman DB, Sweetser S. 52-year-old man with liver enzyme abnormalities and elevated ferritin level. Mayo Clin Proc 2012;87:94-7. [PMID: 22212974 DOI: 10.1016/j.mayocp.2011.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
459 Luo W, Xu Q, Wang Q, Wu H, Hua J. Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. Sci Rep 2017;7:44612. [PMID: 28300213 DOI: 10.1038/srep44612] [Cited by in Crossref: 89] [Cited by in F6Publishing: 92] [Article Influence: 22.3] [Reference Citation Analysis]
460 Paschou SA, Polyzos SA, Anagnostis P, Goulis DG, Kanaka-Gantenbein C, Lambrinoudaki I, Georgopoulos NA, Vryonidou A. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine 2020;67:1-8. [PMID: 31538291 DOI: 10.1007/s12020-019-02085-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
461 Makri E, Cholongitas E, Tziomalos K. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. World J Gastroenterol 2016; 22(41): 9039-9043 [PMID: 27895393 DOI: 10.3748/wjg.v22.i41.9039] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
462 Orešič M, Hyötyläinen T, Kotronen A, Gopalacharyulu P, Nygren H, Arola J, Castillo S, Mattila I, Hakkarainen A, Borra RJ, Honka MJ, Verrijken A, Francque S, Iozzo P, Leivonen M, Jaser N, Juuti A, Sørensen TI, Nuutila P, Van Gaal L, Yki-Järvinen H. Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. Diabetologia 2013;56:2266-74. [PMID: 23824212 DOI: 10.1007/s00125-013-2981-2] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 10.8] [Reference Citation Analysis]
463 Casals G, Perramón M, Casals E, Portolés I, Fernández-Varo G, Morales-Ruiz M, Puntes V, Jiménez W. Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases. Antioxidants (Basel) 2021;10:660. [PMID: 33923136 DOI: 10.3390/antiox10050660] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
464 Desouza CV, Shivaswamy V. Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review. Clin Med Insights Endocrinol Diabetes 2010;3:43-51. [PMID: 22879786 DOI: 10.4137/cmed.s5372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
465 Graebner RC, Wise M, Cuesta-Marcos A, Geniza M, Blake T, Blake VC, Butler J, Chao S, Hole DJ, Horsley R, Jaiswal P, Obert D, Smith KP, Ullrich S, Hayes PM. Quantitative Trait Loci Associated with the Tocochromanol (Vitamin E) Pathway in Barley. PLoS One 2015;10:e0133767. [PMID: 26208213 DOI: 10.1371/journal.pone.0133767] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
466 Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis 2016;20:293-312. [PMID: 27063270 DOI: 10.1016/j.cld.2015.10.011] [Cited by in Crossref: 111] [Cited by in F6Publishing: 90] [Article Influence: 18.5] [Reference Citation Analysis]
467 Snyder HS, Sakaan SA, March KL, Siddique O, Cholankeril R, Cummings CD, Gadiparthi C, Satapathy SK, Ahmed A, Cholankeril G. Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. J Clin Transl Hepatol. 2018;6:168-174. [PMID: 29951362 DOI: 10.14218/jcth.2017.00050] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
468 Gan L, Xiang W, Xie B, Yu L. Molecular mechanisms of fatty liver in obesity. Front Med 2015;9:275-87. [PMID: 26290284 DOI: 10.1007/s11684-015-0410-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
469 Czarnecka K, Czarnecka P, Tronina O, Bączkowska T, Durlik M. Multidirectional facets of obesity management in the metabolic syndrome population after liver transplantation. Immun Inflamm Dis 2021. [PMID: 34598315 DOI: 10.1002/iid3.538] [Reference Citation Analysis]
470 Ibrahim SH, Kohli R, Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr 2011;53:131-40. [PMID: 21629127 DOI: 10.1097/MPG.0b013e31822578db] [Cited by in Crossref: 50] [Cited by in F6Publishing: 81] [Article Influence: 5.0] [Reference Citation Analysis]
471 Carrion AF, Ghanta R, Carrasquillo O, Martin P. Chronic liver disease in the Hispanic population of the United States. Clin Gastroenterol Hepatol 2011;9:834-41; quiz e109-10. [PMID: 21628000 DOI: 10.1016/j.cgh.2011.04.027] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 6.3] [Reference Citation Analysis]
472 Usman M, Bakhtawar N. Vitamin E as an Adjuvant Treatment for Non-alcoholic Fatty Liver Disease in Adults: A Systematic Review of Randomized Controlled Trials. Cureus 2020;12:e9018. [PMID: 32775098 DOI: 10.7759/cureus.9018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
473 Akazawa Y, Nakao K. To die or not to die: death signaling in nonalcoholic fatty liver disease. J Gastroenterol 2018;53:893-906. [PMID: 29574534 DOI: 10.1007/s00535-018-1451-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 12.3] [Reference Citation Analysis]
474 Nagashimada M, Honda M. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics. Int J Mol Sci 2021;22:8008. [PMID: 34360773 DOI: 10.3390/ijms22158008] [Reference Citation Analysis]
475 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 25.5] [Reference Citation Analysis]
476 Ishikawa H, Takaki A, Tsuzaki R, Yasunaka T, Koike K, Shimomura Y, Seki H, Matsushita H, Miyake Y, Ikeda F. L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway. PLoS One. 2014;9:e100627. [PMID: 24983359 DOI: 10.1371/journal.pone.0100627] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
477 Reiniers MJ, van Golen RF, van Gulik TM, Heger M. Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver. Antioxid Redox Signal. 2014;21:1119-1142. [PMID: 24294945 DOI: 10.1089/ars.2013.5486] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 8.4] [Reference Citation Analysis]
478 Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells 2020;9:E1638. [PMID: 32650421 DOI: 10.3390/cells9071638] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
479 Asgharpour A, Dinani A, Friedman SL. Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry. Transl Gastroenterol Hepatol 2021;6:5. [PMID: 33409399 DOI: 10.21037/tgh.2020.01.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
480 Gao X, Fan JG. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. J Diabetes. 2013;5:406-415. [PMID: 23560695 DOI: 10.1111/1753-0407.12056] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 6.8] [Reference Citation Analysis]
481 Argo CK, Patrie JT, Lackner C, Henry TD, de Lange EE, Weltman AL, Shah NL, Al-Osaimi AM, Pramoonjago P, Jayakumar S. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol. 2015;62:190-197. [PMID: 25195547 DOI: 10.1016/j.jhep.2014.08.036] [Cited by in Crossref: 127] [Cited by in F6Publishing: 121] [Article Influence: 18.1] [Reference Citation Analysis]
482 Bedossa P. Current histological classification of NAFLD: Strength and limitations. Hepatol Int. 2013;7 Suppl 2:765-770. [PMID: 26202292 DOI: 10.1007/s12072-013-9446-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
483 Bonsembiante L, Targher G, Maffeis C. Non-alcoholic fatty liver disease in obese children and adolescents: a role for nutrition? Eur J Clin Nutr 2021. [PMID: 34006994 DOI: 10.1038/s41430-021-00928-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
484 Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011;54:1610-9. [PMID: 21748765 DOI: 10.1002/hep.24544] [Cited by in Crossref: 229] [Cited by in F6Publishing: 211] [Article Influence: 22.9] [Reference Citation Analysis]
485 Han E, Lee YH, Lee BW, Kang ES, Cha BS. Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. J Clin Med 2020;9:E259. [PMID: 31963648 DOI: 10.3390/jcm9010259] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
486 Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Kobayashi M, Ikeda K, Kumada H. Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. BMC Gastroenterol 2016;16:141. [PMID: 27955628 DOI: 10.1186/s12876-016-0557-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
487 Komiya C, Tanaka M, Tsuchiya K, Shimazu N, Mori K, Furuke S, Miyachi Y, Shiba K, Yamaguchi S, Ikeda K, Ochi K, Nakabayashi K, Hata KI, Itoh M, Suganami T, Ogawa Y. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Sci Rep 2017;7:44754. [PMID: 28303974 DOI: 10.1038/srep44754] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
488 Ratziu V, Sheikh MY, Sanyal AJ, Lim JK, Conjeevaram H, Chalasani N, Abdelmalek M, Bakken A, Renou C, Palmer M, Levine RA, Bhandari BR, Cornpropst M, Liang W, King B, Mondou E, Rousseau FS, McHutchison J, Chojkier M. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology. 2012;55:419-428. [PMID: 22006541 DOI: 10.1002/hep.24747] [Cited by in Crossref: 120] [Cited by in F6Publishing: 113] [Article Influence: 12.0] [Reference Citation Analysis]
489 Magee N, Zou A, Zhang Y. Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells. Biomed Res Int. 2016;2016:5170402. [PMID: 27822476 DOI: 10.1155/2016/5170402] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 10.8] [Reference Citation Analysis]
490 Liang S, Kisseleva T, Brenner DA. The Role of NADPH Oxidases (NOXs) in Liver Fibrosis and the Activation of Myofibroblasts. Front Physiol. 2016;7:17. [PMID: 26869935 DOI: 10.3389/fphys.2016.00017] [Cited by in Crossref: 78] [Cited by in F6Publishing: 81] [Article Influence: 15.6] [Reference Citation Analysis]
491 Smeuninx B, Boslem E, Febbraio MA. Current and Future Treatments in the Fight Against Non-Alcoholic Fatty Liver Disease. Cancers (Basel) 2020;12:E1714. [PMID: 32605253 DOI: 10.3390/cancers12071714] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
492 Perry RJ. Novel Strategies to Treat Hepatic Steatosis and Steatohepatitis. Obesity (Silver Spring) 2019;27:1385-7. [PMID: 31343116 DOI: 10.1002/oby.22559] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
493 Park S, Cho SM, Jin BR, Yang HJ, Yi QJ. Mixture of blackberry leaf and fruit extracts alleviates non-alcoholic steatosis, enhances intestinal integrity, and increases Lactobacillus and Akkermansia in rats. Exp Biol Med (Maywood) 2019;244:1629-41. [PMID: 31752528 DOI: 10.1177/1535370219889319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
494 Lee HW, Seong SJ, Ohk B, Kang WY, Gwon MR, Kim BK, Kim HJ, Yoon YR. Pharmacokinetic and safety evaluation of MB12066, an NQO1 substrate. Drug Des Devel Ther 2017;11:2719-25. [PMID: 29066863 DOI: 10.2147/DDDT.S142339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
495 Marzuillo P, Giudice EMD, Santoro N. Pediatric non-alcoholic fatty liver disease: New insights and future directions. World J Hepatol 2014; 6(4): 217-225 [PMID: 24799990 DOI: 10.4254/wjh.v6.i4.217] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
496 Birringer M, Blumberg JB, Eggersdorfer M, Frank J, Weber P. History of Vitamin E Research. In: Weber P, Birringer M, Blumberg JB, Eggersdorfer M, Frank J, editors. Vitamin E in Human Health. Cham: Springer International Publishing; 2019. pp. 7-18. [DOI: 10.1007/978-3-030-05315-4_2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
497 Khullar V, Dolganiuc A, Firpi RJ. Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease. World J Transplant 2014; 4(2): 81-92 [PMID: 25032097 DOI: 10.5500/wjt.v4.i2.81] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
498 AbdulHameed MDM, Pannala VR, Wallqvist A. Mining Public Toxicogenomic Data Reveals Insights and Challenges in Delineating Liver Steatosis Adverse Outcome Pathways. Front Genet 2019;10:1007. [PMID: 31681434 DOI: 10.3389/fgene.2019.01007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
499 Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017;37 Suppl 1:97-103. [PMID: 28052626 DOI: 10.1111/liv.13302] [Cited by in Crossref: 107] [Cited by in F6Publishing: 102] [Article Influence: 26.8] [Reference Citation Analysis]
500 Shaker M, Tabbaa A, Albeldawi M, Alkhouri N. Liver transplantation for nonalcoholic fatty liver disease: New challenges and new opportunities. World J Gastroenterol 2014; 20(18): 5320-5330 [PMID: 24833862 DOI: 10.3748/wjg.v20.i18.5320] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 56] [Article Influence: 8.7] [Reference Citation Analysis]
501 Pais R, Moraru I, Ratziu V. Glitazones for human nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2011;4:325-34. [PMID: 21922031 DOI: 10.1177/1756283X11409793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
502 Kuchay MS, Martínez-Montoro JI, Choudhary NS, Fernández-García JC, Ramos-Molina B. Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. Biomedicines 2021;9:1346. [PMID: 34680463 DOI: 10.3390/biomedicines9101346] [Reference Citation Analysis]
503 Okada K, Warabi E, Sugimoto H, Horie M, Tokushige K, Ueda T, Harada N, Taguchi K, Hashimoto E, Itoh K. Nrf2 inhibits hepatic iron accumulation and counteracts oxidative stress-induced liver injury in nutritional steatohepatitis. J Gastroenterol. 2012;47:924-935. [PMID: 22367278 DOI: 10.1007/s00535-012-0552-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 5.2] [Reference Citation Analysis]
504 Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659-68. [PMID: 21521847 DOI: 10.1001/jama.2011.520] [Cited by in Crossref: 662] [Cited by in F6Publishing: 582] [Article Influence: 66.2] [Reference Citation Analysis]
505 Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
506 Ozturk ZA, Kadayifci A. Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World J Hepatol 2014; 6(4): 199-206 [PMID: 24799988 DOI: 10.4254/wjh.v6.i4.199] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
507 Wegermann K, Diehl AM, Moylan CA. Disease pathways and molecular mechanisms of nonalcoholic steatohepatitis. Clin Liver Dis (Hoboken) 2018;11:87-91. [PMID: 30992796 DOI: 10.1002/cld.709] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
508 Mirrakhimov AE, Polotsky VY. Obstructive sleep apnea and non-alcoholic Fatty liver disease: is the liver another target? Front Neurol. 2012;3:149. [PMID: 23087670 DOI: 10.3389/fneur.2012.00149] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
509 Yan H, Wu W, Chang X, Xia M, Ma S, Wang L, Gao J. Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. Biol Sex Differ 2021;12:1. [PMID: 33397443 DOI: 10.1186/s13293-020-00344-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
510 Wang Z, Li Z, Ye Y, Xie L, Li W. Oxidative Stress and Liver Cancer: Etiology and Therapeutic Targets. Oxid Med Cell Longev 2016;2016:7891574. [PMID: 27957239 DOI: 10.1155/2016/7891574] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 10.8] [Reference Citation Analysis]
511 Thiagarajan P, Aithal GP. Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges. J Clin Exp Hepatol 2019;9:515-21. [PMID: 31516268 DOI: 10.1016/j.jceh.2019.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
512 Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:221-35. [PMID: 33317243 DOI: 10.3350/cmh.2020.0239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
513 Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World J Hepatol 2021; 13(11): 1584-1610 [DOI: 10.4254/wjh.v13.i11.1584] [Reference Citation Analysis]
514 Day CP. Non-alcoholic fatty liver disease: a massive problem. Clin Med. 2011;11:176-178. [PMID: 21526706 DOI: 10.7861/clinmedicine.11-2-1761] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
515 Niki E. Evidence for beneficial effects of vitamin E. Korean J Intern Med 2015;30:571-9. [PMID: 26354050 DOI: 10.3904/kjim.2015.30.5.571] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
516 Yates KP, Deppe R, Comerford M, Masuoka H, Cummings OW, Tonascia J, Chalasani N, Vuppalanchi R; NASH CRN. Serum high mobility group box 1 protein levels are not associated with either histological severity or treatment response in children and adults with nonalcoholic fatty liver disease. PLoS One 2017;12:e0185813. [PMID: 29095942 DOI: 10.1371/journal.pone.0185813] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
517 Ruart M, Chavarria L, Campreciós G, Suárez-herrera N, Montironi C, Guixé-muntet S, Bosch J, Friedman SL, Garcia-pagán JC, Hernández-gea V. Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. Journal of Hepatology 2019;70:458-69. [DOI: 10.1016/j.jhep.2018.10.015] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 18.7] [Reference Citation Analysis]
518 Li S, Ghoshal S, Sojoodi M, Arora G, Masia R, Erstad DJ, Lanuti M, Hoshida Y, Baumert TF, Tanabe KK, Fuchs BC. Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. J Gastrointest Surg. 2019;23:101-111. [PMID: 30367397 DOI: 10.1007/s11605-018-4004-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
519 He Z, Li X, Yang H, Wu P, Wang S, Cao D, Guo X, Xu Z, Gao J, Zhang W, Luo X. Effects of Oral Vitamin C Supplementation on Liver Health and Associated Parameters in Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Front Nutr 2021;8:745609. [PMID: 34595203 DOI: 10.3389/fnut.2021.745609] [Reference Citation Analysis]
520 Pennisi G, Celsa C, Spatola F, Dallio M, Federico A, Petta S. Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. Int J Environ Res Public Health 2019;16:E4334. [PMID: 31703268 DOI: 10.3390/ijerph16224334] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
521 Bazelier MT, de Vries F, Vestergaard P, Herings RM, Gallagher AM, Leufkens HG, van Staa TP. Risk of fracture with thiazolidinediones: an individual patient data meta-analysis. Front Endocrinol (Lausanne) 2013;4:11. [PMID: 23549934 DOI: 10.3389/fendo.2013.00011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
522 Brownell J, Polyak SJ. Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res. 2013;19:1347-1352. [PMID: 23322900 DOI: 10.1158/1078-0432.ccr-12-0928] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 5.1] [Reference Citation Analysis]
523 Li W, Alazawi W. Non-alcoholic fatty liver disease. Clin Med (Lond) 2020;20:509-12. [PMID: 32934047 DOI: 10.7861/clinmed.2020-0696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
524 Lee SM, Muratalla J, Diaz-Ruiz A, Remon-Ruiz P, McCann M, Liew CW, Kineman RD, Cordoba-Chacon J. Rosiglitazone Requires Hepatocyte PPARγ Expression to Promote Steatosis in Male Mice With Diet-Induced Obesity. Endocrinology 2021;162:bqab175. [PMID: 34417811 DOI: 10.1210/endocr/bqab175] [Reference Citation Analysis]
525 Bhat G, Baba CS, Pandey A, Kumari N, Choudhuri G. Life style modification improves insulin resistance and liver histology in patients with non-alcoholic fatty liver disease. World J Hepatol 2012; 4(7): 209-217 [PMID: 22855696 DOI: 10.4254/wjh.v4.i7.209] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
526 Lin CW, Zhang H, Li M, Xiong X, Chen X, Chen X, Dong XC, Yin XM. Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice. J Hepatol. 2013;58:993-999. [PMID: 23339953 DOI: 10.1124/10.1016/j.jhep.2013.01.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
527 Tsedensodnom O, Sadler KC. ROS: redux and paradox in fatty liver disease. Hepatology 2013;58:1210-2. [PMID: 23703804 DOI: 10.1002/hep.26497] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
528 Wettstein G, Luccarini JM, Poekes L, Faye P, Kupkowski F, Adarbes V, Defrêne E, Estivalet C, Gawronski X, Jantzen I, Philippot A, Tessier J, Tuyaa-Boustugue P, Oakley F, Mann DA, Leclercq I, Francque S, Konstantinova I, Broqua P, Junien JL. The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis. Hepatol Commun 2017;1:524-37. [PMID: 29404476 DOI: 10.1002/hep4.1057] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 12.3] [Reference Citation Analysis]
529 Yang X, Chang X, Wu S, Sun X, Zhu X, Wang L, Xu Y, Yao X, Rao S, Hu X, Xia M, Bian H, Yan H, Gao X. Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease. Lipids Health Dis 2021;20:27. [PMID: 33757528 DOI: 10.1186/s12944-021-01453-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
530 Roeb E. Non-alcoholic fatty liver diseases: current challenges and future directions. Ann Transl Med 2021;9:726. [PMID: 33987424 DOI: 10.21037/atm-20-3760] [Reference Citation Analysis]
531 Chi-Cervera LA, Montalvo GI, Icaza-Chávez ME, Torres-Romero J, Arana-Argáez V, Ramírez-Camacho M, Lara-Riegos J. Clinical relevance of lipid panel and aminotransferases in the context of hepatic steatosis and fibrosis as measured by transient elastography (FibroScan®). J Med Biochem 2021;40:60-6. [PMID: 33584141 DOI: 10.5937/jomb0-24689] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
532 Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(13): 3777-3785 [PMID: 25852263 DOI: 10.3748/wjg.v21.i13.3777] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 68] [Article Influence: 11.5] [Reference Citation Analysis]
533 Weiß J, Rau M, Geier A. Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int 2014;111:447-52. [PMID: 25019921 DOI: 10.3238/arztebl.2014.0447] [Cited by in Crossref: 19] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
534 Dibba P, Li AA, Perumpail BJ, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD. Diseases 2018;6:E83. [PMID: 30235807 DOI: 10.3390/diseases6030083] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
535 Samala N, Tersey SA, Chalasani N, Anderson RM, Mirmira RG. Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase. J Diabetes Complications 2017;31:1630-7. [PMID: 28886991 DOI: 10.1016/j.jdiacomp.2017.07.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
536 Jansen PLM, Breuhahn K, Teufel A, Dooley S. Editorial: Systems Biology and Bioinformatics in Gastroenterology and Hepatology. Front Physiol 2019;10:1438. [PMID: 31824341 DOI: 10.3389/fphys.2019.01438] [Reference Citation Analysis]
537 Yao Z, Liu XC, Gu YE. Schisandra chinensis Baill, a Chinese medicinal herb, alleviates high-fat-diet-inducing non-alcoholic steatohepatitis in rats. Afr J Tradit Complement Altern Med 2014;11:222-7. [PMID: 24653581 DOI: 10.4314/ajtcam.v11i1.35] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
538 Tripathy A, Thakurela S, Sahu MK, Uthansingh K, Singh A, Narayan J, Ajay AK, Singh V, Kumari R. Fatty changes associated with N-Nitrosodiethylamine (DEN) induced hepatocellular carcinoma: a role of sonic hedgehog signaling pathway. Genes Cancer 2020;11:66-82. [PMID: 32577158 DOI: 10.18632/genesandcancer.203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
539 Cave MC, Clair HB, Hardesty JE, Falkner KC, Feng W, Clark BJ, Sidey J, Shi H, Aqel BA, McClain CJ. Nuclear receptors and nonalcoholic fatty liver disease. Biochim Biophys Acta. 2016;1859:1083-1099. [PMID: 26962021 DOI: 10.1016/j.bbagrm.2016.03.002] [Cited by in Crossref: 126] [Cited by in F6Publishing: 121] [Article Influence: 25.2] [Reference Citation Analysis]
540 Shin SK, Cho HW, Song SE, Song DK. Catalase and nonalcoholic fatty liver disease. Pflugers Arch 2018;470:1721-37. [PMID: 30120555 DOI: 10.1007/s00424-018-2195-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
541 Dai Y, He H, Li S, Yang L, Wang X, Liu Z, An Z. Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 2020;11:622589. [PMID: 33664710 DOI: 10.3389/fendo.2020.622589] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
542 Portillo-Sanchez P, Cusi K. Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. Clin Diabetes Endocrinol 2016;2:9. [PMID: 28702244 DOI: 10.1186/s40842-016-0027-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
543 Parlati L, Régnier M, Guillou H, Postic C. New targets for NAFLD. JHEP Rep 2021;3:100346. [PMID: 34667947 DOI: 10.1016/j.jhepr.2021.100346] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
544 Nakamura A, Zhu Q, Yokoyama Y, Kitamura N, Uchida S, Kumadaki K, Tsubota K, Watanabe M. Agaricus brasiliensis KA21 May Prevent Diet-Induced Nash Through Its Antioxidant, Anti-Inflammatory, and Anti-Fibrotic Activities in the Liver. Foods 2019;8:E546. [PMID: 31689883 DOI: 10.3390/foods8110546] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
545 Cuschieri JR, John BK, Miick R, Ortiz JA, Hashemi N. Successful Treatment of Rapid Onset, Symptomatic de novo Non-alcoholic Steatohepatitis Following Liver Transplantation: A Case Report. J Clin Exp Hepatol 2013;3:70-4. [PMID: 25755474 DOI: 10.1016/j.jceh.2013.01.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
546 Miyanishi K, Hoki T, Tanaka S, Kato J. Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy. World J Hepatol 2015; 7(3): 593-599 [PMID: 25848483 DOI: 10.4254/wjh.v7.i3.593] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
547 Marks KM, Kitch D, Chung RT, Hadigan C, Andersen J, Tien P, Luetkemeyer A, Alston-Smith B, Glesby MJ; A5239 Team. Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239. J Acquir Immune Defic Syndr 2014;65:345-9. [PMID: 24525470 DOI: 10.1097/QAI.0000000000000073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
548 Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol. 2014;7:221-239. [PMID: 25045276 DOI: 10.2147/ceg.s62831] [Cited by in Crossref: 53] [Cited by in F6Publishing: 114] [Article Influence: 7.6] [Reference Citation Analysis]
549 Shafiq M, Walmann T, Nutalapati V, Gibson C, Zafar Y. Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver. World J Hepatol 2020; 12(12): 1258-1167 [PMID: 33442452 DOI: 10.4254/wjh.v12.i12.1258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
550 Sharma BC, Kumar A, Garg V, Reddy RS, Sakhuja P, Sarin SK. A Randomized Controlled Trial Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in Patients with Non-alcoholic Steatohepatitis. J Clin Exp Hepatol. 2012;2:333-337. [PMID: 25755455 DOI: 10.1016/j.jceh.2012.10.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
551 Okishio S, Yamaguchi K, Ishiba H, Tochiki N, Yano K, Takahashi A, Kataoka S, Okuda K, Seko Y, Liu Y, Fujii H, Takahashi D, Ito Y, Kamon J, Umemura A, Moriguchi M, Yasui K, Okanoue T, Itoh Y. PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat. Sci Rep 2020;10:19578. [PMID: 33177546 DOI: 10.1038/s41598-020-75805-z] [Reference Citation Analysis]
552 Mindikoglu AL, Opekun AR, Gagan SK, Devaraj S. Impact of Time-Restricted Feeding and Dawn-to-Sunset Fasting on Circadian Rhythm, Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract 2017;2017:3932491. [PMID: 29348746 DOI: 10.1155/2017/3932491] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
553 Alkhouri N, Poordad F, Lawitz E. Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes. Hepatol Commun. 2018;2:778-785. [PMID: 30027137 DOI: 10.1002/hep4.1195] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
554 Yang M, Gong S, Ye SQ, Lyman B, Geng L, Chen P, Li DY. Non-alcoholic fatty liver disease in children: focus on nutritional interventions. Nutrients 2014;6:4691-705. [PMID: 25353664 DOI: 10.3390/nu6114691] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
555 Kleiner DE, Berk PD, Hsu JY, Courcoulas AP, Flum D, Khandelwal S, Pender J, Pomp A, Roerig J, Machado LL, Wolfe BM, Belle SH; LABS Consortium. Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the longitudinal assessment of bariatric surgery (LABS) study. Semin Liver Dis 2014;34:98-107. [PMID: 24782263 DOI: 10.1055/s-0034-1371083] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
556 Suárez M, Boqué N, Del Bas JM, Mayneris-Perxachs J, Arola L, Caimari A. Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease. Nutrients 2017;9:E1052. [PMID: 28937599 DOI: 10.3390/nu9101052] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 9.5] [Reference Citation Analysis]
557 Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307-318. [PMID: 23458891 DOI: 10.1038/nrgastro.2013.34] [Cited by in Crossref: 278] [Cited by in F6Publishing: 267] [Article Influence: 34.8] [Reference Citation Analysis]
558 Baršić N, Lerotić I, Smirčić-Duvnjak L, Tomašić V, Duvnjak M. Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18(30): 3945-3954 [PMID: 22912545 DOI: 10.3748/wjg.v18.i30.3945] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
559 Esler WP, Bence KK. Metabolic Targets in Nonalcoholic Fatty Liver Disease. Cell Mol Gastroenterol Hepatol 2019;8:247-67. [PMID: 31004828 DOI: 10.1016/j.jcmgh.2019.04.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 19.0] [Reference Citation Analysis]
560 Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012;35:66-75. [PMID: 22050199 DOI: 10.1111/j.1365-2036.2011.04912.x] [Cited by in Crossref: 186] [Cited by in F6Publishing: 167] [Article Influence: 18.6] [Reference Citation Analysis]
561 Mehal WZ, Schuppan D. Antifibrotic therapies in the liver. Semin Liver Dis. 2015;35:184-198. [PMID: 25974903 DOI: 10.1055/s-0035-1550055] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
562 Burrin DG, Ng K, Stoll B, Sáenz De Pipaón M. Impact of new-generation lipid emulsions on cellular mechanisms of parenteral nutrition-associated liver disease. Adv Nutr. 2014;5:82-91. [PMID: 24425726 DOI: 10.3945/an.113.004796] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 7.1] [Reference Citation Analysis]
563 Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA; Nonalcoholic Steatohepatitis Clinical Research Network. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology 2019;70:522-31. [PMID: 30549292 DOI: 10.1002/hep.30418] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
564 Sayiner M, Lam B, Golabi P, Younossi ZM. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2018;11:1756284818811508. [PMID: 30479664 DOI: 10.1177/1756284818811508] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
565 Arai T, Atsukawa M, Tsubota A, Mikami S, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Emoto N, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K. Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data. Ther Adv Endocrinol Metab 2021;12:20420188211000243. [PMID: 33815743 DOI: 10.1177/20420188211000243] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
566 Conjeevaram Selvakumar PK, Kabbany MN, Alkhouri N. Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. Paediatr Drugs. 2018;20:315-329. [PMID: 29740791 DOI: 10.1007/s40272-018-0292-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
567 Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest. 2013;123:1887-1901. [PMID: 23635787 DOI: 10.1172/jci66028] [Cited by in Crossref: 393] [Cited by in F6Publishing: 226] [Article Influence: 49.1] [Reference Citation Analysis]
568 Gillessen A, Schmidt HH. Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. Adv Ther 2020;37:1279-301. [PMID: 32065376 DOI: 10.1007/s12325-020-01251-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 26.0] [Reference Citation Analysis]
569 Shen T, Xu B, Lei T, Chen L, Zhang C, Ni Z. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway. Exp Ther Med 2018;16:3121-8. [PMID: 30214535 DOI: 10.3892/etm.2018.6554] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
570 Wu J. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Oncotarget 2016;7:42762-76. [PMID: 27072576 DOI: 10.18632/oncotarget.8641] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
571 Martínez Soriano B, Güemes A, Pola G, Gonzalo A, Palacios Gasós P, Navarro AC, Martínez-Beamonte R, Osada J, García JJ. Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model. Can J Gastroenterol Hepatol 2020;2020:7315253. [PMID: 32566547 DOI: 10.1155/2020/7315253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
572 Lian J, Fu J. Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes: A Network Meta-Analysis. Front Endocrinol (Lausanne) 2021;12:649018. [PMID: 33841337 DOI: 10.3389/fendo.2021.649018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
573 Aktary ML, Eller LK, Nicolucci AC, Reimer RA. Cross-sectional analysis of the health profile and dietary intake of a sample of Canadian adults diagnosed with non-alcoholic fatty liver disease.Food Nutr Res. 2020;64. [PMID: 33061886 DOI: 10.29219/fnr.v64.4548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
574 Zisser A, Ipsen DH, Tveden-Nyborg P. Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis-Roles as Putative Treatment Targets? Biomedicines 2021;9:365. [PMID: 33807461 DOI: 10.3390/biomedicines9040365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
575 Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149:389-97.e10. [PMID: 25935633 DOI: 10.1053/j.gastro.2015.04.043] [Cited by in Crossref: 1264] [Cited by in F6Publishing: 1171] [Article Influence: 210.7] [Reference Citation Analysis]
576 Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Res 2018;7:F1000 Faculty Rev-921. [PMID: 30002817 DOI: 10.12688/f1000research.14841.1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 13.7] [Reference Citation Analysis]
577 Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease. Intern Med 2020;59:329-38. [PMID: 31534089 DOI: 10.2169/internalmedicine.3555-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
578 Munteanu MA, Nagy GA, Mircea PA. Current Management of NAFLD. Clujul Med 2016;89:19-23. [PMID: 27004021 DOI: 10.15386/cjmed-539] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
579 Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, Arrese M, Fracanzani AL, Ben Bashat D, Lackner K, Gorfine T, Kadosh S, Oren R, Halperin M, Hayardeny L, Loomba R, Friedman S, Sanyal AJ; ARREST investigator study group. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med 2021;27:1825-35. [PMID: 34621052 DOI: 10.1038/s41591-021-01495-3] [Reference Citation Analysis]
580 Zhang F, Kong D, Lu Y, Zheng S. Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside. Cell Mol Life Sci 2013;70:259-76. [DOI: 10.1007/s00018-012-1046-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
581 Baran B, Akyüz F. Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning? World J Gastroenterol 2014; 20(39): 14219-14229 [PMID: 25339808 DOI: 10.3748/wjg.v20.i39.14219] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
582 Luo Y, Oseini A, Gagnon R, Charles ED, Sidik K, Vincent R, Collen R, Idowu M, Contos MJ, Mirshahi F, Daita K, Asgharpour A, Siddiqui MS, Jarai G, Rosen G, Christian R, Sanyal AJ. An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis. Sci Rep. 2018;8:12414. [PMID: 30120271 DOI: 10.1038/s41598-018-30457-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
583 Damiris K, Tafesh ZH, Pyrsopoulos N. Efficacy and safety of anti-hepatic fibrosis drugs. World J Gastroenterol 2020; 26(41): 6304-6321 [PMID: 33244194 DOI: 10.3748/wjg.v26.i41.6304] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
584 Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Kunimoto H, Sorin Y, Fujiyama S, Sezaki H, Hosaka T. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan. Hepatol Int. 2016;10:647-656. [PMID: 27074850 DOI: 10.1007/s12072-016-9729-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
585 Anania FA. Non-alcoholic fatty liver disease and fructose: bad for us, better for mice. J Hepatol 2011;55:218-20. [PMID: 21338637 DOI: 10.1016/j.jhep.2011.01.029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
586 Pacana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2012;15:641-648. [PMID: 23075940 DOI: 10.1097/mco.0b013e328357f747] [Cited by in Crossref: 70] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
587 Bourgi K, Wanjalla C, Koethe JR. Inflammation and Metabolic Complications in HIV. Curr HIV/AIDS Rep 2018;15:371-81. [PMID: 30058057 DOI: 10.1007/s11904-018-0411-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
588 Kargiotis K, Athyros VG, Giouleme O, Katsiki N, Katsiki E, Anagnostis P, Boutari C, Doumas M, Karagiannis A, Mikhailidis DP. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21(25): 7860-7868 [PMID: 26167086 DOI: 10.3748/wjg.v21.i25.7860] [Cited by in CrossRef: 81] [Cited by in F6Publishing: 66] [Article Influence: 13.5] [Reference Citation Analysis]
589 Wu YK, Ren ZN, Zhu SL, Wu YZ, Wang G, Zhang H, Chen W, He Z, Ye XL, Zhai QX. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway. Acta Pharmacol Sin 2021. [PMID: 34654875 DOI: 10.1038/s41401-021-00786-2] [Reference Citation Analysis]
590 Alam S, Kabir J, Mustafa G, Gupta U, Hasan SK, Alam AK. Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial. Saudi J Gastroenterol. 2016;22:69-76. [PMID: 26831610 DOI: 10.4103/1319-3767.173762] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
591 Bedossa P. Histological Assessment of NAFLD. Dig Dis Sci. 2016;61:1348-1355. [PMID: 26874689 DOI: 10.1007/S10620-016-4052-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
592 Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019;6:e821-30. [PMID: 31611038 DOI: 10.1016/S2352-3018(19)30338-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 13.5] [Reference Citation Analysis]
593 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol 2014; 20(36): 12956-12980 [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 109] [Cited by in F6Publishing: 91] [Article Influence: 15.6] [Reference Citation Analysis]
594 Yodoshi T, Orkin S, Arce-Clachar AC, Bramlage K, Su W, Fei L, Xanthakos SA, Mouzaki M. Identifying Predictors of Response to Vitamin E for the Treatment of Pediatric Nonalcoholic Steatohepatitis. JPEN J Parenter Enteral Nutr 2020;44:1301-7. [PMID: 31985850 DOI: 10.1002/jpen.1766] [Reference Citation Analysis]
595 Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016;13:196-205. [PMID: 26907882 DOI: 10.1038/nrgastro.2016.3] [Cited by in Crossref: 150] [Cited by in F6Publishing: 144] [Article Influence: 30.0] [Reference Citation Analysis]
596 Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904. [DOI: 10.1007/s00125-011-2446-4] [Cited by in Crossref: 366] [Cited by in F6Publishing: 343] [Article Influence: 40.7] [Reference Citation Analysis]
597 Vos MB, Colvin R, Belt P, Molleston JP, Murray KF, Rosenthal P, Schwimmer JB, Tonascia J, Unalp A, Lavine JE; NASH CRN Research Group. Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. J Pediatr Gastroenterol Nutr. 2012;54:90-96. [PMID: 22197855 DOI: 10.1097/mpg.0b013e318229da1a] [Cited by in Crossref: 77] [Cited by in F6Publishing: 39] [Article Influence: 8.6] [Reference Citation Analysis]
598 Hofmann WP, Buggisch P, Schubert L, Dikopoulos N, Schwenzer J, Muche M, Felten G, Heyne R, Ingiliz P, Schmidt A, Stein K, Wedemeyer H, Berg T, Wiegand J, Lammert F, Zeuzem S, Schattenberg JM. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.JHEP Rep. 2020;2:100168. [PMID: 32964201 DOI: 10.1016/j.jhepr.2020.100168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
599 Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. BMC Gastroenterol 2018;18:165. [PMID: 30400829 DOI: 10.1186/s12876-018-0900-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
600 Cholankeril R, Patel V, Perumpail BJ, Yoo ER, Iqbal U, Sallam S, Shah ND, Kwong W, Kim D, Ahmed A. Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. Diseases 2018;6:E93. [PMID: 30282916 DOI: 10.3390/diseases6040093] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
601 Ndugga N, Lightbourne TG, Javaherian K, Cabezas J, Verma N, Barritt AS 4th, Bataller R. Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA. BMJ Open 2017;7:e013620. [PMID: 28336739 DOI: 10.1136/bmjopen-2016-013620] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
602 Yang H, Suh DH, Kim DH, Jung ES, Liu KH, Lee CH, Park CY. Metabolomic and lipidomic analysis of the effect of pioglitazone on hepatic steatosis in a rat model of obese Type 2 diabetes. Br J Pharmacol 2018;175:3610-25. [PMID: 29968381 DOI: 10.1111/bph.14434] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
603 Kamm DR, Pyles KD, Sharpe MC, Healy LN, Colca JR, McCommis KS. Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide. J Biol Chem 2021;296:100807. [PMID: 34022222 DOI: 10.1016/j.jbc.2021.100807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
604 Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y. The Role of Oxidative Stress and Antioxidants in Liver Diseases. Int J Mol Sci. 2015;16:26087-26124. [PMID: 26540040 DOI: 10.3390/ijms161125942] [Cited by in Crossref: 610] [Cited by in F6Publishing: 502] [Article Influence: 101.7] [Reference Citation Analysis]
605 Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F, Chou HL, Hashiguchi T, Plato C, Poulin D, Richards T, Yoneyama H, Jenkins H, Wolfgang G, Friedman SL. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016;11:e0158156. [PMID: 27347680 DOI: 10.1371/journal.pone.0158156] [Cited by in Crossref: 160] [Cited by in F6Publishing: 152] [Article Influence: 32.0] [Reference Citation Analysis]
606 Thuy LTT, Hai H, Kawada N. Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis. Clin Mol Hepatol 2020;26:280-93. [PMID: 32492766 DOI: 10.3350/cmh.2020.0037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
607 Mehta SR. Advances in the treatment of nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab. 2010;1:101-115. [PMID: 23148155 DOI: 10.1177/2042018810379587] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
608 Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K, Busetto L, Frühbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek GH, Vinker S, Ungan M, Mendive JM, Lionis C. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021;3:100322. [PMID: 34693236 DOI: 10.1016/j.jhepr.2021.100322] [Reference Citation Analysis]
609 Rikhi R, Singh T, Modaresi Esfeh J. Work up of fatty liver by primary care physicians, review. Ann Med Surg (Lond) 2020;50:41-8. [PMID: 31993196 DOI: 10.1016/j.amsu.2020.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
610 Singer C, Stancu P, Coşoveanu S, Botu A. Non-alcoholic Fatty liver disease in children. Curr Health Sci J. 2014;40:170-176. [PMID: 25729601 DOI: 10.12865/CHSJ.40.03.03] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
611 Stine JG, Xu D, Schmitz K, Sciamanna C, Kimball SR. Exercise Attenuates Ribosomal Protein Six Phosphorylation in Fatty Liver Disease. Dig Dis Sci 2020;65:3238-43. [PMID: 32239376 DOI: 10.1007/s10620-020-06226-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
612 Schmölz L, Schubert M, Kluge S, Birringer M, Wallert M, Lorkowski S. The Hepatic Fate of Vitamin E. In: Morales-gonzalez JA, editor. Vitamin E in Health and Disease. InTech; 2018. [DOI: 10.5772/intechopen.79445] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
613 Castillo V, Figueroa F, González-Pizarro K, Jopia P, Ibacache-Quiroga C. Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review. Foods 2021;10:1719. [PMID: 34441497 DOI: 10.3390/foods10081719] [Reference Citation Analysis]
614 Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol. 2016;22:91-105. [PMID: 26997214 DOI: 10.4103/1319-3767.178527] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
615 Gangopadhyay KK, Singh P. Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. Indian J Endocrinol Metab 2017;21:341-54. [PMID: 28459036 DOI: 10.4103/ijem.IJEM_512_16] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
616 Hardy T, Anstee QM, Day CP. Nonalcoholic fatty liver disease: new treatments. Curr Opin Gastroenterol. 2015;31:175-183. [PMID: 25774446 DOI: 10.1097/mog.0000000000000175] [Cited by in Crossref: 61] [Cited by in F6Publishing: 32] [Article Influence: 12.2] [Reference Citation Analysis]
617 Sarkhy AA, Al-Hussaini AA, Nobili V. Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis. Saudi J Gastroenterol. 2014;20:143-153. [PMID: 24976277 DOI: 10.4103/1319-3767.132983] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
618 Yki-Järvinen H. Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance. Nutrients 2015;7:9127-38. [PMID: 26556368 DOI: 10.3390/nu7115454] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 14.2] [Reference Citation Analysis]
619 Chang MI, Puder M, Gura KM. The use of fish oil lipid emulsion in the treatment of intestinal failure associated liver disease (IFALD). Nutrients 2012;4:1828-50. [PMID: 23363993 DOI: 10.3390/nu4121828] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
620 Lee BW, Lee YH, Park CY, Rhee EJ, Lee WY, Kim NH, Choi KM, Park KG, Choi YK, Cha BS, Lee DH; Korean Diabetes Association (KDA) Fatty Liver Research Group. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. Diabetes Metab J 2020;44:382-401. [PMID: 32431115 DOI: 10.4093/dmj.2020.0010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
621 Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol 2021;56:951-63. [PMID: 34533632 DOI: 10.1007/s00535-021-01796-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
622 Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, Gill R, Loomba R, Diehl AM, Aouizerat BE; NASH Clinical Research Network. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology 2017;65:65-77. [PMID: 27532276 DOI: 10.1002/hep.28776] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 15.4] [Reference Citation Analysis]
623 Tavaglione F, Targher G, Valenti L, Romeo S. Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinol Diabetes Metab 2020;3:e00179. [PMID: 33102799 DOI: 10.1002/edm2.179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
624 Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1-21. [PMID: 22511898 DOI: 10.3350/kjhep.2012.18.1.1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 10.4] [Reference Citation Analysis]
625 Bedossa P. Histological Assessment of NAFLD. Dig Dis Sci. 2016;61:1348-1355. [PMID: 26874689 DOI: 10.1007/s10620-016-4062-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
626 Banini BA, Sanyal AJ. Current and future pharmacologic treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2017;33:134-41. [PMID: 28346237 DOI: 10.1097/MOG.0000000000000356] [Cited by in Crossref: 36] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
627 Vonghia L, Van Herck MA, Weyler J, Francque S. Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease. Front Immunol 2019;10:563. [PMID: 30972062 DOI: 10.3389/fimmu.2019.00563] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
628 Kim GH, Chung JW, Lee JH, Ok KS, Jang ES, Kim J, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Kim JW. Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study. Clin Mol Hepatol 2015;21:379-86. [PMID: 26770927 DOI: 10.3350/cmh.2015.21.4.379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
629 Banini BA, Sanyal AJ. Treatment of NASH: What Helps Beyond Weight Loss? Am J Gastroenterol 2017;112:821-4. [PMID: 28397875 DOI: 10.1038/ajg.2017.83] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
630 Van Gaal LF, Mertens J, Francque S, De Block C. Therapeutic approaches for non-alcoholic steatohepatitis. Ther Adv Endocrinol Metab 2021;12:20420188211034300. [PMID: 34497708 DOI: 10.1177/20420188211034300] [Reference Citation Analysis]
631 Pydyn N, Miękus K, Jura J, Kotlinowski J. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis. Pharmacol Rep 2020;72:1-12. [PMID: 32016853 DOI: 10.1007/s43440-019-00020-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 19.0] [Reference Citation Analysis]
632 Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism 2016;65:1096-108. [PMID: 26856933 DOI: 10.1016/j.metabol.2016.01.001] [Cited by in Crossref: 205] [Cited by in F6Publishing: 195] [Article Influence: 41.0] [Reference Citation Analysis]
633 Gao L, Zhang Z, Zhang P, Yu M, Yang T. Role of canonical Hedgehog signaling pathway in liver. Int J Biol Sci. 2018;14:1636-1644. [PMID: 30416378 DOI: 10.7150/ijbs.28089] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
634 Said A. Non-alcoholic fatty liver disease and liver transplantation: Outcomes and advances. World J Gastroenterol 2013; 19(48): 9146-9155 [PMID: 24409043 DOI: 10.3748/wjg.v19.i48.9146] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
635 Singal AK, Jampana SC, Weinman SA. Antioxidants as therapeutic agents for liver disease. Liver Int. 2011;31:1432-1448. [PMID: 22093324 DOI: 10.1111/j.1478-3231.2011.02604.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 109] [Article Influence: 12.9] [Reference Citation Analysis]
636 Lai GY, Weinstein SJ, Taylor PR, McGlynn KA, Virtamo J, Gail MH, Albanes D, Freedman ND. Effects of α-tocopherol and β-carotene supplementation on liver cancer incidence and chronic liver disease mortality in the ATBC study. Br J Cancer 2014;111:2220-3. [PMID: 25314069 DOI: 10.1038/bjc.2014.514] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
637 张国, 胡烨, 陆伦根. 肝纤维化诊治机遇与挑战. 世界华人消化杂志 2015; 23(36): 5743-5749 [DOI: 10.11569/wcjd.v23.i36.5743] [Reference Citation Analysis]
638 Zhang S, Wong YT, Tang KY, Kwan HY, Su T. Chinese Medicinal Herbs Targeting the Gut-Liver Axis and Adipose Tissue-Liver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science. Front Endocrinol (Lausanne) 2020;11:572729. [PMID: 33101207 DOI: 10.3389/fendo.2020.572729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
639 Hall RA, Liebe R, Hochrath K, Kazakov A, Alberts R, Laufs U, Böhm M, Fischer HP, Williams RW, Schughart K, Weber SN, Lammert F. Systems genetics of liver fibrosis: identification of fibrogenic and expression quantitative trait loci in the BXD murine reference population. PLoS One 2014;9:e89279. [PMID: 24586654 DOI: 10.1371/journal.pone.0089279] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
640 Zhang TS, Qin HL, Wang T, Li HT, Li H, Xia SH, Xiang XH. Global publication trends and research hotspots of nonalcoholic fatty liver disease: a bibliometric analysis and systematic review. Springerplus. 2015;4:776. [PMID: 26697286 DOI: 10.1186/s40064-015-1542-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
641 David D, Eapen CE. What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease? J Clin Exp Hepatol 2021;11:232-8. [PMID: 33746449 DOI: 10.1016/j.jceh.2020.09.001] [Reference Citation Analysis]
642 Odagiri N, Matsubara T, Sato-Matsubara M, Fujii H, Enomoto M, Kawada N. Anti-fibrotic treatments for chronic liver diseases: The present and the future. Clin Mol Hepatol 2021;27:413-24. [PMID: 33317250 DOI: 10.3350/cmh.2020.0187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
643 Yang JS, Kim JT, Jeon J, Park HS, Kang GH, Park KS, Lee HK, Kim S, Cho YM. Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice. PLoS One 2010;5:e13858. [PMID: 21079772 DOI: 10.1371/journal.pone.0013858] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
644 Richard J, Lingvay I. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther. 2011;9:321-328. [PMID: 21438811 DOI: 10.1586/erc.11.15] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
645 Kim KS, Lee BW, Kim YJ, Lee DH, Cha BS, Park CY. Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment. Diabetes Metab J 2019;43:127-43. [PMID: 30993937 DOI: 10.4093/dmj.2019.0034] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 19.0] [Reference Citation Analysis]
646 Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. The Role of Vitamin E in the Treatment of NAFLD. Diseases 2018;6:E86. [PMID: 30249972 DOI: 10.3390/diseases6040086] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 9.3] [Reference Citation Analysis]
647 Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, Richards L, Salotti J, Bhatt A, Hooker J, Haufe W, Hooker C, Brenner DA, Sirlin CB, Loomba R. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J Hepatol. 2016;65:369-376. [PMID: 27151177 DOI: 10.1016/j.jhep.2016.04.021] [Cited by in Crossref: 186] [Cited by in F6Publishing: 169] [Article Influence: 37.2] [Reference Citation Analysis]
648 Jamali R, Moghtadaie A, Miratashi Yazdi SA, Moghtadaie H. Impact of standard treatment on the quality of life of non-alcoholic fatty liver disease patients. J Taibah Univ Med Sci 2021;16:755-60. [PMID: 34690658 DOI: 10.1016/j.jtumed.2021.03.010] [Reference Citation Analysis]
649 Yoo JJ, Kim W, Kim MY, Jun DW, Kim SG, Yeon JE, Lee JW, Cho YK, Park SH, Sohn JH; the Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG). Recent research trends and updates on nonalcoholic fatty liver disease. Clin Mol Hepatol 2019;25:1-11. [PMID: 30086613 DOI: 10.3350/cmh.2018.0037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 11.7] [Reference Citation Analysis]
650 Tanwar S, Rhodes F, Srivastava A, Trembling PM, Rosenberg WM. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. World J Gastroenterol 2020; 26(2): 109-133 [PMID: 31969775 DOI: 10.3748/wjg.v26.i2.109] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 22.0] [Reference Citation Analysis]
651 Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des 2013;19:5250-69. [PMID: 23394092 DOI: 10.2174/13816128113199990344] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 13.4] [Reference Citation Analysis]
652 Dyson JK, Anstee QM, McPherson S. Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. Postgrad Med J 2015;91:92-101. [PMID: 25655252 DOI: 10.1136/postgradmedj-2013-100404rep] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
653 Skat-Rørdam J, Højland Ipsen D, Lykkesfeldt J, Tveden-Nyborg P. A role of peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease. Basic Clin Pharmacol Toxicol 2019;124:528-37. [PMID: 30561132 DOI: 10.1111/bcpt.13190] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 17.5] [Reference Citation Analysis]
654 Campo L, Eiseler S, Apfel T, Pyrsopoulos N. Fatty Liver Disease and Gut Microbiota: A Comprehensive Update. J Clin Transl Hepatol. 2019;7:56-60. [PMID: 30944821 DOI: 10.14218/jcth.2018.00008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 6.3] [Reference Citation Analysis]
655 Kita Y, Takamura T, Misu H, Ota T, Kurita S, Takeshita Y, Uno M, Matsuzawa-Nagata N, Kato K, Ando H. Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PLoS One. 2012;7:e43056. [PMID: 23028442 DOI: 10.1371/journal.pone.0043056] [Cited by in Crossref: 84] [Cited by in F6Publishing: 82] [Article Influence: 9.3] [Reference Citation Analysis]
656 Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, Malek M, Reza Babaei M, Zamani F, Ajdarkosh H, Khoonsari M, Fallah AE, Khamseh ME. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Diabetes Ther. 2021;12:843-861. [PMID: 33586120 DOI: 10.1007/s13300-021-01011-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
657 Regev A, Palmer M, Avigan MI, Dimick-Santos L, Treem WR, Marcinak JF, Seekins D, Krishna G, Anania FA, Freston JW, Lewis JH, Sanyal AJ, Chalasani N. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2019;49:702-13. [PMID: 30761572 DOI: 10.1111/apt.15153] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
658 Kennedy-Martin T, Bae JP, Paczkowski R, Freeman E. Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review. J Patient Rep Outcomes 2017;2:28. [PMID: 29984351 DOI: 10.1186/s41687-018-0052-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
659 Cobbold JFL, Raveendran S, Peake CM, Anstee QM, Yee MS, Thursz MR. Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease: initial 5-year experience. Frontline Gastroenterol 2013;4:263-9. [PMID: 28839736 DOI: 10.1136/flgastro-2013-100319] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
660 Gautheron J, Gores GJ, Rodrigues CMP. Lytic cell death in metabolic liver disease. J Hepatol 2020;73:394-408. [PMID: 32298766 DOI: 10.1016/j.jhep.2020.04.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 21.0] [Reference Citation Analysis]
661 Alkhouri N, Feldstein AE. The TONIC trial: a step forward in treating pediatric nonalcoholic fatty liver disease. Hepatology 2012;55:1292-5. [PMID: 22461076 DOI: 10.1002/hep.24767] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
662 Bazerbachi F, Vargas EJ, Rizk M, Maselli DB, Mounajjed T, Venkatesh SK, Watt KD, Port JD, Basu R, Acosta A, Hanouneh I, Gara N, Shah M, Mundi M, Clark M, Grothe K, Storm AC, Levy MJ, Abu Dayyeh BK. Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2021;19:146-154.e4. [PMID: 32360804 DOI: 10.1016/j.cgh.2020.04.068] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
663 Sharma P, Arora A. Approach to prevention of non-alcoholic fatty liver disease after liver transplantation. Transl Gastroenterol Hepatol 2020;5:51-51. [DOI: 10.21037/tgh.2020.03.02] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
664 Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocr Connect 2020;9:R173-86. [PMID: 32621584 DOI: 10.1530/EC-20-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
665 Cave M, Falkner KC, Henry L, Costello B, Gregory B, McClain CJ. Serum cytokeratin 18 and cytokine elevations suggest a high prevalence of occupational liver disease in highly exposed elastomer/polymer workers. J Occup Environ Med 2011;53:1128-33. [PMID: 21915069 DOI: 10.1097/JOM.0b013e31822cfd68] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
666 Liss KH, Finck BN. PPARs and nonalcoholic fatty liver disease. Biochimie 2017;136:65-74. [PMID: 27916647 DOI: 10.1016/j.biochi.2016.11.009] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 20.6] [Reference Citation Analysis]
667 Enosawa S, Dozen M, Tada Y, Hirasawa K. Electron Therapy Attenuated Elevated Alanine Aminotransferase and Oxidative Stress Values in Type 2 Diabetes-Induced Nonalcoholic Steatohepatitis of Rats. Cell Med 2013;6:63-73. [PMID: 26858882 DOI: 10.3727/215517913X674225] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
668 McVicker BL, Bennett RG. Novel Anti-fibrotic Therapies. Front Pharmacol 2017;8:318. [PMID: 28620300 DOI: 10.3389/fphar.2017.00318] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
669 Egnatchik RA, Leamy AK, Noguchi Y, Shiota M, Young JD. Palmitate-induced activation of mitochondrial metabolism promotes oxidative stress and apoptosis in H4IIEC3 rat hepatocytes. Metabolism. 2014;63:283-295. [PMID: 24286856 DOI: 10.1016/j.metabol.2013.10.009] [Cited by in Crossref: 92] [Cited by in F6Publishing: 84] [Article Influence: 11.5] [Reference Citation Analysis]
670 Rupcic Rubin V, Bojanic K, Smolic M, Rubin J, Tabll A, Smolic R. An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents. J Clin Transl Hepatol 2021;9:60-70. [PMID: 33604256 DOI: 10.14218/JCTH.2020.00040] [Reference Citation Analysis]
671 Tacelli M, Celsa C, Magro B, Giannetti A, Pennisi G, Spatola F, Petta S. Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? Pharmaceuticals (Basel). 2018;11:121. [PMID: 30413050 DOI: 10.3390/ph11040121] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
672 Ng K, Stoll B, Chacko S, Saenz de Pipaon M, Lauridsen C, Gray M, Squires EJ, Marini J, Zamora IJ, Olutoye OO, Burrin DG. Vitamin E in New-Generation Lipid Emulsions Protects Against Parenteral Nutrition-Associated Liver Disease in Parenteral Nutrition-Fed Preterm Pigs. JPEN J Parenter Enteral Nutr 2016;40:656-71. [PMID: 25596209 DOI: 10.1177/0148607114567900] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 6.7] [Reference Citation Analysis]
673 Alkhouri N, Berk M, Yerian L, Lopez R, Chung YM, Zhang R, McIntyre TM, Feldstein AE, Hazen SL. OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci 2014;59:1617-24. [PMID: 24464211 DOI: 10.1007/s10620-014-3031-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
674 Aghamohammadzadeh N, Niafar M, Dalir Abdolahinia E, Najafipour F, Mohamadzadeh Gharebaghi S, Adabi K, Dalir Abdolahinia E, Ahadi H. The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients. Ther Adv Endocrinol Metab. 2015;6:56-60. [PMID: 25941563 DOI: 10.1177/2042018815574229] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
675 Hasenour CM, Kennedy AJ, Bednarski T, Trenary IA, Eudy BJ, da Silva RP, Boyd KL, Young JD. Vitamin E does not prevent Western diet-induced NASH progression and increases metabolic flux dysregulation in mice. J Lipid Res 2020;61:707-21. [PMID: 32086244 DOI: 10.1194/jlr.RA119000183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
676 Zhang PW, Chen FX, Li D, Ling WH, Guo HH. A CONSORT-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease. Medicine (Baltimore). 2015;94:e758. [PMID: 25997043 DOI: 10.1097/MD.0000000000000758] [Cited by in Crossref: 50] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
677 Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307-318. [PMID: 23458891 DOI: 10.1038/nrgastro.2013. 34] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
678 Ferolla SM, Ferrari TC, Lima ML, Reis TO, Tavares WC Jr, Couto OF, Vidigal PV, Fausto MA, Couto CA. Dietary patterns in Brazilian patients with nonalcoholic fatty liver disease: a cross-sectional study. Clinics (Sao Paulo) 2013;68:11-7. [PMID: 23420151 DOI: 10.6061/clinics/2013(01)oa03] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
679 Gawrieh S, Wilson LA, Yates KP, Cummings OW, Vilar-Gomez E, Ajmera V, Kowdley KV, Rosenberg WM, Tonascia J, Chalasani N. Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. Hepatol Commun 2021;5:786-97. [PMID: 34027269 DOI: